

CITATION REPORT

List of articles citing

Ulcerative colitis and colorectal cancer. A population-based study

DOI: 10.1056/nejm199011013231802

New England Journal of Medicine, 1990, 323, 1228-33.

Source: <https://exaly.com/paper-pdf/21837808/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1613	Using ordinal logistic regression to estimate the likelihood of colorectal neoplasia. 1991 , 44, 1263-70		16
1612	<i>Helicobacter pylori</i> infection and gastric carcinoma among Japanese Americans in Hawaii. <i>New England Journal of Medicine</i> , 1991 , 325, 1132-6	59.2	1578
1611	Colonic epithelial dysplasia or carcinoma in a regional group of patients with ulcerative colitis of more than 15 years duration. 1991 , 230, 259-63		13
1610	Colon cancer incidence: recent trends in the United States. 1991 , 2, 419-25		22
1609	Screening for colorectal cancer in ulcerative colitis. 1991 , 32, 721-722		1
1608	Inflammatory bowel disease (2). <i>New England Journal of Medicine</i> , 1991 , 325, 1008-16	59.2	276
1607	Gastrointestinal endoscopy (2). <i>New England Journal of Medicine</i> , 1991 , 325, 1214-22	59.2	21
1606	Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age at onset on colitis-cancer interval. 1991 , 32, 167-9		117
1605	Letters to the editor. 1991 , 32, 722-3		5
1604	Colorectal cancer screening. 1991 , 83, 243-53		117
1603	Screening for colorectal cancer. <i>New England Journal of Medicine</i> , 1991 , 325, 37-41	59.2	133
1602	DNA aneuploidy in Crohn's disease and ulcerative colitis: results of a comparative flow cytometric study. 1992 , 33, 663-7		33
1601	Survival and causes of death in patients with inflammatory bowel disease: a population-based study. 1992 , 103, 954-60		229
1600	Surveillance in the routine management of ulcerative colitis: the predictive value of low-grade dysplasia. 1992 , 103, 431-8		167
1599	Colorectal cancer risk and mortality in patients with ulcerative colitis. 1992 , 103, 1444-51		419
1598	DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. 1992 , 103, 1611-20		463
1597	Multiple microcarcinoids arising in chronic ulcerative colitis. 1992 , 98, 112-6		22

1596 Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. **1992**, 15, 417

1595 Ileal pouch-anal anastomosis. **1992**, 29, 57-131

42

1594 Epidémiologie du cancer colorectal. **1992**, 22, 75-80

1593 Ulcerative colitis and colon cancer: biology and surveillance. **1992**, 16G, 47-50

31

1592 Inflammatory bowel disease and colon cancer. **1992**, 70, 1313-6

48

1591 Recent advances in surgery for colon and rectal cancer. **1993**, 17, 1-65

15

1590 Colorectal cancer in Denmark 1943-1988. **1993**, 8, 42-7

15

1589 Practice parameters for the treatment of rectal carcinoma—Supporting documentation. **1993**, 36, 991-1006

7

1588 Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. **1993**, 36, 908-12

102

1587 Colon cancer prevention update. **1993**, 9, 163-8

1586 Pancreatitis and the risk of pancreatic cancer. *New England Journal of Medicine*, **1993**, 329, 1502-3

59.2 29

1585 Colon cancer: a review of the epidemiology. **1993**, 15, 499-545

613

1584 Inflammatory bowel disease. **1993**, 40, 1213-31

3

1583 Clinical and colonoscopic surveillance in ulcerative colitis: are we saving colons or saving lives?. **1993**, 105, 588-97

16

1582 Pathogenesis of colorectal cancer. **1993**, 73, 1-11

5

1581 Screening strategies for colorectal cancer. **1993**, 73, 31-45

6

1580 Case-control Study of Bowel Habits and Colorectal Adenoma and Cancer. **1993**, 3, 1-5

4

1579 Increased risk of left sided colon cancer in patients with diverticular disease. **1993**, 34, 499-502

62

1578	Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. 1994 , 35, 1590-2	383
1577	Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. 1994 , 35, 950-4	286
1576	Cancer in Crohn's disease: dispelling the myths. 1994 , 35, 1507-8	89
1575	Colonoscopic surveillance in ulcerative colitis. 1994 , 35, 429-30	1
1574	Role of adrenocortical steroids in mediating cancer-preventive and age-retarding effects of food restriction in laboratory rodents. 1994 , 49, B37-41	23
1573	Marqueurs biologiques spécifiques et facteurs des maladies inflammatoires de l'intestin. 1994 , 8, 29-38	
1572	Current surgical therapy for mucosal ulcerative colitis. 1994 , 37, 610-24	32
1571	Diseases preceding colon cancer. A case-control study among veterans. 1994 , 39, 2480-4	48
1570	Ulcerative colitis and coexisting colorectal cancer: recurrence rate after restorative proctocolectomy. 1994 , 1, 512-5	31
1569	Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?. 1994 , 343, 71-4	489
1568	Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. 1994 , 107, 117-20	299
1567	Surgical treatment of inflammatory bowel disease. 1994 , 78, 1427-41	1
1566	Cancer in inflammatory bowel disease. 1994 , 78, 1399-412	21
1565	Colorectal cancer in patients with ulcerative colitis. A prospective cohort study in Italy. 1995 , 75, 2045-50	28
1564	Cancer in patients with ulcerative colitis. 1995 , 60, 330-3	103
1563	Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. 1995 , 22, 1404-8	329
1562	Incidence of colorectal cancer and all cause mortality in non-selected patients with ulcerative colitis and indeterminate colitis in MalmöSweden. 1995 , 10, 117-22	55
1561	Premalignant changes in ulcerative colitis. 1995 , 11, 386-93	4

1560 Prise en charge des patients à risque de cancer colorectal héréditaire. **1995**, 25, 63-70

1559 Colite ulcéreuse chronique et cancer colorectal. **1995**, 25, 71-80

1558 Cancer Risk in Inflammatory Bowel Disease. **1995**, 9, 23-26

5

1557 Alterations of p53 and k-ras genes in human colorectal-cancer with ulcerative-colitis. **1995**, 6, 767-72

1556 Protection by endoscopy against death from colorectal cancer. A case-control study among veterans. **1995**, 155, 1741-8

225

1555 C. **1995**, 497-886

1554 Colitis ulcerosa complicated by malignant lymphoma: case report and analysis of published works. **1995**, 36, 306-10

30

1553 Is colonoscopic cancer surveillance in ulcerative colitis essential for every patient?. **1995**, 31A, 1178-82

11

1552 Right lower quadrant pain in a 31-year-old woman with ulcerative colitis. **1995**, 98, 291-302

1551 Long-term histomorphological surveillance of the pelvic ileal pouch: dysplasia develops in a subgroup of patients. **1995**, 109, 1090-7

155

1550 Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis. **1995**, 109, 1188-96

95

1549 Colitic cancer: supervision, surveillance, or surgery?. **1995**, 109, 1388-91

17

1548 Physiological regulation of intestinal epithelial tight junctions as a consequence of Na(+)-coupled nutrient transport. **1995**, 109, 1391-6

63

1547 Low incidence of significant dysplasia in a successful endoscopic surveillance program of patients with ulcerative colitis. **1995**, 108, 1361-70

89

1546 Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential*1. **1995**, 22, 1404-1408

269

1545 Folate status, DNA methylation and colon cancer risk in inflammatory bowel disease. **1995**, 14, 50-53

15

1544 Unifying hypothesis for inflammatory bowel disease and associated colon cancer: sticking the pieces together with sugar. **1996**, 347, 40-4

97

1543 Ileal pouch-anal anastomosis for ulcerative colitis and polyposis coli: is the risk of carcinoma formation conclusively averted?. **1996**, 22, 372-6

20

1542	Influence of inflammatory bowel disease on the ability of patients to tolerate systemic fluorouracil-based chemotherapy. 1996 , 14, 2043-6	22
1541	Sulphasalazine Use as a Preventive Factor for Colorectal Cancer in Ulcerative Colitis Patients: A Review. 1996 , 2, 276-278	4
1540	Colorectal Cancer in Ulcerative Colitis: Survival in Patients With and Without Colorectal Cancer Symptoms. 1996 , 2, 6-10	4
1539	Hereditary cancer: two hits revisited. 1996 , 122, 135-40	377
1538	Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. 1996 , 111, 323-31; discussion 331-3	95
1537	Colorectal cancer in ulcerative colitis: Survival in patients with and without colorectal cancer symptoms. 1996 , 2, 6-10	5
1536	Significance and detection of dysplasia in chronic colitis. 1996 , 78, 2261-3	43
1535	DNA hypomethylation and proliferative activity are increased in the rectal mucosa of patients with long-standing ulcerative colitis. 1996 , 78, 2300-6	47
1534	Retrospective review of colorectal cancer in ulcerative colitis at a tertiary center. 1996 , 131, 806-10; discussion 810-1	25
1533	Long-term results after colectomy and ileoanal pull-through procedure in children. 1996 , 131, 881-5; discussion 885-6	38
1532	Twenty years' colonoscopic surveillance of patients with ulcerative colitis. Detection of dysplastic and malignant transformation. 1996 , 31, 1195-204	83
1531	Inhibition of 7,12-dimethylbenz[a]anthracene-induced lung tumorigenesis in A/J mice by food restriction is reversed by adrenalectomy. 1996 , 17, 209-12	42
1530	Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity, and mortality in a regional cohort. 1997 , 32, 139-47	199
1529	Inflammatory bowel diseases: health care and costs in Sweden in 1994. 1997 , 32, 1134-9	138
1528	Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. 1997 , 41, 522-5	206
1527	Colorectal dysplasia and carcinoma in patients with ulcerative colitis and primary sclerosing cholangitis. 1997 , 32, 706-11	49
1526	Interactions Between Chronic Liver Disease and Inflammatory Bowel Disease. 1997 , 3, 288-302	43
1525	Risk factors for the development of colorectal carcinoma and their modification. 1997 , 11, 547-77	4

- 1524 Screening and Surveillance of Ulcerative Colitis. **1997**, 7, 129-145 7
- 1523 Contributions of the Molecular Biologist in Gastrointestinal Cancer and Precancer Screening: Current Possibilities and Future Prospects. **1997**, 7, 147-164 1
- 1522 Cancer Biology in Ulcerative Colitis and Potential Use in Endoscopic Surveillance. **1997**, 7, 453-468 20
- 1521 Evaluation of surveillance programmes for colorectal cancer in ulcerative colitis patients by case-control studies: methodological considerations. **1997**, 4, 137-41 5
- 1520 Inflammatory bowel disease and colon cancer: a review. **1997**, 15, 243-52 23
- 1519 Review: the surgical management of ulcerative colitis. **1997**, 12, 670-7 10
- 1518 Mechanistic studies on genotoxicity and carcinogenicity of salicylazosulfapyridine an anti-inflammatory medicine. **1997**, 49, 15-28 11
- 1517 Place de l'endoscopie dans le choix thérapeutique au cours des MICI. **1997**, 27, 289-293
- 1516 Quand faut-il refaire une endoscopie au cours des maladies inflammatoires chroniques de l'intestin?. **1997**, 27, 301-304
- 1515 Surveillance endoscopique des maladies inflammatoires chroniques de l'intestin: fondement, méthodes et considérations pratiques. **1997**, 27, 129-143 2
- 1514 Overview of the epidemiology of colorectal cancer. **1997**, 40, 483-93 72
- 1513 Practice parameters for the treatment of mucosal ulcerative colitis--supporting documentation. The Standards Practice Task Force. The American Society of Colon and Rectal Surgeons. **1997**, 40, 1277-85 19
- 1512 Completion proctectomy in ulcerative colitis. **1997**, 84, 436-437
- 1511 Interactions Between Chronic Liver Disease and Inflammatory Bowel Disease. **1997**, 3, 288-302 49
- 1510 Colon polyps. **1997**, 66, 207-14 16
- 1509 Primary malignancies as a secondary disease. **1998**, 9, 355-6
- 1508 [Carcinoma in chronic inflammatory bowel diseases]. **1998**, 39, 1024-9 4
- 1507 Biology of colorectal cancer in ulcerative colitis. **1998**, 2, 307-11 3

1506	Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. 1998 , 27, 311-6	209
1505	Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. 1998 , 27, 685-90	169
1504	Challenges in designing a randomized trial of surveillance colonoscopy in IBD. 1998 , 4, 132-41	17
1503	Die Koinzidenz von Kolonadenomen und Kolonkarzinomen bei der Divertikulitis. 1998 , 20, 90-98	
1502	Ileal pouch-anal anastomosis in patients with colorectal cancer: long-term functional and oncologic outcomes. 1998 , 41, 11-7	45
1501	[Colorectal carcinoma. Prevention and early detection]. 1998 , 39, W509-18	
1500	[Colorectal carcinoma. Prevention and early detection]. 1998 , 37, W431-9	
1499	Risk of cancer in ulcerative colitis. 1998 , 2, 312-3	28
1498	How reliable/valid is dysplasia in identifying at-risk patients with ulcerative colitis?. 1998 , 2, 314-7	15
1497	Vulvar lichen sclerosus and squamous cell carcinoma: a cohort, case control, and investigational study with historical perspective; implications for chronic inflammation and sclerosis in the development of neoplasia. 1998 , 29, 932-48	202
1496	Sialyl-Tn antigen as a marker of colon cancer risk in ulcerative colitis: relation to dysplasia and DNA aneuploidy. 1998 , 115, 1395-404	55
1495	Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. 1998 , 115, 1079-83	189
1494	Family history as a risk factor for ulcerative colitis-associated colon cancer in cotton-top tamarin. 1998 , 114, 669-74	24
1493	Liver transplantation and inflammatory bowel disease. 1998 , 28, 1070-6	15
1492	Colon carcinoma in patients undergoing liver transplantation. 1998 , 176, 265-9	57
1491	Identification of dithiolethione-inducible gene-1 as a leukotriene B4 12-hydroxydehydrogenase: implications for chemoprevention. 1998 , 19, 999-1005	45
1490	Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. 1998 , 43, 639-44	147
1489	Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. 1998 , 42, 711-4	240

1488	General and cancer specific mortality of a population based cohort of patients with inflammatory bowel disease: the Florence Study. 1998 , 42, 175-9	119
1487	Microsatellite instability in non-neoplastic mucosa of patients with ulcerative colitis: effect of folate supplementation. 1998 , 93, 2060-4	48
1486	Challenges in Designing a Randomized Trial of Surveillance Colonoscopy in IBD. 1998 , 4, 132-141	12
1485	Risk factors and distinguishing features of cancer in IBD. 1998 , 4, 235-43	9
1484	Antidiarrheal agents for the management of treatment-related diarrhea in cancer patients. 1998 , 55, 1573-80	34
1483	Ulcerative colitis and colon cancer: more controversy than clarity. 1998 , 16, 81-7	15
1482	A simple model for carcinogenesis of colorectal cancers with microsatellite instability. 2000 , 77, 189-221	20
1481	Increased risk for cancer following sarcoidosis. 1999 , 160, 1668-72	202
1480	11. Appropriateness of colonoscopy: inflammatory bowel disease. 1999 , 31, 647-53	11
1479	Molecular screening of patients with long standing extensive ulcerative colitis: detection of p53 and Ki-ras mutations by single strand conformation polymorphism analysis and differential hybridisation in colonic lavage fluid. 1999 , 44, 822-5	32
1478	Primary sclerosing cholangitis and cholangiocarcinoma as a diagnostic and therapeutic dilemma. 1999 , 10, S89-S93	16
1477	Immunohistochemical evaluation of Bcl-2 gene family expression in liver of hepatitis C and cirrhotic patients: a novel mechanism to explain the high incidence of hepatocarcinoma in cirrhotics. 1999 , 94, 178-82	39
1476	Increased risk of cancer in ulcerative colitis: a population-based cohort study. 1999 , 94, 1047-52	159
1475	The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. 1999 , 94, 1643-9	196
1474	Evaluation of the usefulness of testing for p53 mutations in colorectal cancer surveillance for ulcerative colitis. 1999 , 94, 456-62	74
1473	Practice parameters for the management of colonic cancer II: other issues. Recommendations of the Colorectal Surgical Society of Australia. 1999 , 69, 472-8	
1472	Chronic active disease reffects cancer risk in ulcerative colitis. 1999 , 90, 1066-70	6
1471	Renal Cell Carcinoma Associated with Ulcerative Colitis. 1999 , 31, 751-753	

- ¹⁴⁷⁰ Increased colonic ornithine decarboxylase activity in inflammatory bowel disease in children. **1999**, 44, 1565-70 17
- ¹⁴⁶⁹ Practice parameters for detection of colorectal neoplasms. The Standards Committee, The American Society of Colon and Rectal Surgeons. **1999**, 42, 1123-9 41
- ¹⁴⁶⁸ MICI et cancer colorectal. Surveillance. **1999**, 29, 243-251
- ¹⁴⁶⁷ Detection of colonic dysplasia by light-induced fluorescence endoscopy: a pilot study. **1999**, 14, 63-8 32
- ¹⁴⁶⁶ Increased expression of proliferative Ki-67 nuclear antigen is correlated with dysplastic colorectal epithelium in ulcerative colitis. **1999**, 14, 107-13 21
- ¹⁴⁶⁵ Cancer surveillance in inflammatory bowel disease. **1999**, 1, 496-504 13
- ¹⁴⁶⁴ Inflammatory bowel disease in pediatric and adolescent patients. **1999**, 28, 445-58 143
- ¹⁴⁶³ Inflammatory bowel disease. **1999**, 26, 141-70 14
- ¹⁴⁶² Colorectal cancer screening. **1999**, 83, 1403-22, vi 13
- ¹⁴⁶¹ Chronic inflammation and cancer: potential role of Bcl-2 gene family members as regulators of cellular antioxidant status. **1999**, 52, 27-30 22
- ¹⁴⁶⁰ Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. **1999**, 117, 1295-300 296
- ¹⁴⁵⁹ Risk of cancer in ulcerative colitis. **1999**, 49, S60-2 14
- ¹⁴⁵⁸ Epidemiology and the natural course of inflammatory bowel disease. **1999**, 28, 255-81, vii 206
- ¹⁴⁵⁷ Cancer risk in patients with inflammatory bowel disease. **1999**, 28, 459-77, x 104
- ¹⁴⁵⁶ Increased risk of cancer in ulcerative colitis: a population-based cohort study. **1999**, 94, 1047-1052 9
- ¹⁴⁵⁵ Genetic instability and the mutator phenotype. Studies in ulcerative colitis. **1999**, 154, 1621-6 56
- ¹⁴⁵⁴ Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. **1999**, 154, 1825-30 153
- ¹⁴⁵³ Management of women at risk for malignancy. **2000**, 12, 508-13

1452	Colorectal cancer prevention in ulcerative colitis: a case-control study. 2000 , 14, 145-53	423
1451	Cyclooxygenase-2 and carcinogenesis. 2000 , 1470, M69-78	159
1450	The case for colorectal cancer screening. 2000 , 35, 325-32	3
1449	Age-related clinical severity at diagnosis in 1705 patients with ulcerative colitis: a study by GISC (Italian Colon-Rectum Study Group). 2000 , 45, 462-5	51
1448	Expression of hepatocyte growth factor and c-met in ulcerative colitis. 2000 , 49, 320-4	29
1447	Colon cancer. 2000 , 43, 1473-86	13
1446	Dysplasia complicating chronic ulcerative colitis: is immediate colectomy warranted?. 2000 , 43, 1575-81	65
1445	Aneuploidy and columnar cuff surveillance after stapled ileal pouch-anal anastomosis in ulcerative colitis. 2000 , 43, 408-13	26
1444	Ulcerative colitis and cancer. 2000 , 3, 189-191	
1443	Liver involvement in patients operated for ulcerative colitis, with special reference to the association of cholangitis with colorectal dysplasia and carcinoma. 2000 , 15, 167-71	16
1442	Colorectal Cancer. 2000 ,	6
1441	Colorectal cancer complicating ulcerative colitis: a review. 2000 , 95, 2710-9	85
1440	Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. 2000 , 47, 514-9	183
1439	MAGGOT LABORATORY CONTROL. 2000 , 25,	
1438	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 28-2000. A 34-year-old man with ulcerative colitis and a large perirectal mass. <i>New England Journal of Medicine</i> , 2000 , 343, 794-800	59.2 9
1437	Ernährung in der perioperativen Phase bei chronisch entzündlichen Darmerkrankungen. 2000 , 35, 62-68	
1436	Cclooxygenase-2 (COX-2) Protein Expression by Western Blotting. 2001 , 50, 205-11	
1435	Hyperplastic-like mucosal change in Crohn's disease: an unusual form of dysplasia?. 2000 , 13, 797-801	42

1434	[Colonic carcinoma associated with ulcerative colitis. Risk factors, molecular pathogenesis and surveillance]. 2000 , 125, 1045-50	4
1433	[Colorectal carcinoma: prevention and early detection in an asymptomatic population--prevention in patients at risk--endoscopic diagnosis, therapy and after-care of polyps and carcinomas. German Society of Digestive and Metabolic Diseases/Study Group for Gastrointestinal Oncology]. 2000 , 38, 49-75	61
1432	High frequencies of telomeric associations, chromosome aberrations, and sister chromatid exchanges in ulcerative colitis. 2000 , 95, 2301-7	27
1431	Use of large medical databases to study associations between diseases. 2000 , 93, 669-75	74
1430	Defective hMSH2/hMLH1 protein expression is seen infrequently in ulcerative colitis associated colorectal cancers. 2000 , 46, 367-9	33
1429	Surveying surveillance: are gastroenterologists consistently inconsistent, inconsistently consistent, or poorly educated?. 2000 , 51, 240-2	8
1428	Surveillance colonoscopy in inflammatory bowel disease. 2000 , 2, 18-22	
1427	Risk of cancer in inflammatory bowel disease (IBD). 2000 , 11, 75-78	14
1426	Chromosomal alterations in ulcerative colitis-related and sporadic colorectal cancers by comparative genomic hybridization. 2000 , 31, 109-14	55
1425	Survival and incidence of colorectal cancer in patients with ulcerative colitis in Funen county diagnosed between 1973 and 1993. 2000 , 35, 312-7	26
1424	Intestinal mucosal secretion of basic fibroblast growth factor in patients with ulcerative colitis. 2000 , 35, 408-12	24
1423	Mice harboring a defective epidermal growth factor receptor (waved-2) have an increased susceptibility to acute dextran sulfate-induced colitis. 2000 , 35, 1181-7	51
1422	Transforming growth factor-alpha and epidermal growth factor receptor in colonic mucosa in active and inactive inflammatory bowel disease. 2000 , 18, 79-91	20
1421	Colitis ulcerosa. 2000 , 8, 283-287	
1420	The cause of colorectal cancer. 2000 , 32, 426-39	23
1419	Pathogenesis of colorectal cancer. 2000 , 32, 807-21	28
1418	Hodgkin's disease risk is increased in patients with ulcerative colitis. 2000 , 119, 647-53	112
1417	Leukotrienes induce cell-survival signaling in intestinal epithelial cells. 2000 , 119, 1007-18	94

1416	Effects of dietary folate on DNA strand breaks within mutation-prone exons of the p53 gene in rat colon. 2000 , 119, 151-61	75
1415	Principles of Cancer Surgery. 2001 , 1577-1595	
1414	Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. 2001 , 120, 841-7	180
1413	Screening and surveillance colonoscopy in chronic Crohn's colitis. 2001 , 120, 820-6	206
1412	Family history as a risk factor for colorectal cancer in inflammatory bowel disease. 2001 , 120, 1356-62	327
1411	Risk of dysplasia in long-term ileal pouches and pouches with chronic pouchitis. 2001 , 121, 275-81	93
1410	The role of mutant Apc in the development of dysplasia and cancer in the mouse model of dextran sulfate sodium-induced colitis. 2001 , 121, 1407-16	89
1409	Pathology of colorectal cancer. 2001 , 33, 372-88	64
1408	[Crohn's disease and small intestine adenocarcinoma]. 2001 , 22, 749-52	0
1407	Inflammation, carcinogenesis and cancer. 2001 , 1, 1651-67	109
1406	Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study. 2001 , 357, 262-6	80
1405	Inflammation and cancer: back to Virchow?. 2001 , 357, 539-45	5588
1404	Inflammatory bowel disease. 2001 , 28, 539-56, vi	17
1403	The risk of colorectal cancer in ulcerative colitis: a meta-analysis. 2001 , 48, 526-35	1974
1402	Transforming Growth Factor-alpha (TGF-a) is Not Needed for Malignant Transformation in Experimental Colitis. 2001 , 36, 276-282	
1401	Ulcerative Colitis and Colorectal Carcinoma: DNA-Profile, Laminin-5 ?2 Chain and Cyclin A Expression as Early Markers for Risk Assessment. 2001 , 36, 751-758	25
1400	Surveillance issues in inflammatory bowel disease: ulcerative colitis. 2001 , 32, 99-105	54
1399	Rectal lymphoma in ulcerative colitis treated with azathioprine. 2001 , 13, 989-92	10

1398	Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. 2001 , 134, 89-95	324
1397	Increased expression of metallothionein in inflammatory bowel disease. 2001 , 50, 289-93	30
1396	Flow cytometric and histologic evaluation in a large cohort of patients with ulcerative colitis: correlation with clinical characteristics and impact on surveillance. 2001 , 44, 1446-55	9
1395	Maladies inflammatoires chroniques de l'intestin. 2001 , 31, 576-582	
1394	The role of gene-environment interaction in the aetiology of human cancer: examples from cancers of the large bowel, lung and breast. 2001 , 249, 477-93	92
1393	Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. 2001 , 194, 152-7	197
1392	Cancer risk in patients with inflammatory bowel disease: a population-based study. 2001 , 91, 854-62	932
1391	Diagnostic value of DNA image cytometry in ulcerative colitis. 2001 , 46, 870-8	10
1390	The methylenetetrahydrofolate reductase (MTHFR) gene in colorectal cancer: role in tumor development and significance of allelic loss in tumor progression. 2001 , 30, 105-11	23
1389	Advantages and disadvantages of population screening for cancer and surveillance of at-risk groups. 2001 , 15, 211-26	6
1388	Epidemiology of inflammatory bowel disease in Asia. 2001 , 7, 260-70	176
1387	Mutations of p53 in morphologically non-neoplastic mucosa of long-standing ulcerative colitis. 2001 , 92, 119-26	12
1386	Relevance of folate metabolism in the pathogenesis of colorectal cancer. 2001 , 138, 164-76	60
1385	Risk factors for uterine leiomyoma: a practice-based case-control study. II. Atherogenic risk factors and potential sources of uterine irritation. 2001 , 153, 11-9	112
1384	The comorbid occurrence of other diagnoses in patients with ulcerative colitis and Crohn's disease. 2001 , 96, 2107-12	33
1383	Transforming growth factor-alpha (TGF-alpha) is not needed for malignant transformation in experimental colitis. 2001 , 36, 276-82	
1382	Ulcerative colitis and colorectal carcinoma: DNA-profile, laminin-5 gamma2 chain and cyclin A expression as early markers for risk assessment. 2001 , 36, 751-8	31
1381	Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: fact or fiction?. 2001 , 48, 430-4	72

1380	Colorectal Cancer Screening and Surveillance. 2001 , 14, 359-368	1
1379	What should be the standard care for cancer surveillance, diagnosis of dysplasia, and the decision for colectomy in chronic inflammatory bowel disease?. 2002 , 97, 1249-55	2
1378	Inhibition of chronic ulcerative colitis-associated colorectal adenocarcinoma development in a murine model by N-acetylcysteine. 2002 , 23, 993-1001	77
1377	Surgery of Colon Cancer. 2002 , 267-290	
1376	Wallenberg's lateral medullary syndrome. 2002 , 78, 618	
1375	Risk of pancreatic adenocarcinoma in chronic pancreatitis. 2002 , 51, 849-52	305
1374	Physiology of folic acid in health and disease. 2002 , 3, 211-23	120
1373	Does patient knowledge affect the colorectal cancer risk in ulcerative colitis?. 2002 , 78, 615-8	8
1372	Incidence of inflammatory bowel disease in children in southeastern Norway: a prospective population-based study 1990-94. 2002 , 37, 540-5	68
1371	Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. 2002 , 51 Suppl 5, V10-2	287
1370	Screening for p53 and K-ras mutations in whole-gut lavage in chronic inflammatory bowel disease. 2002 , 14, 1061-6	15
1369	Colorectal Cancer. 2002 ,	2
1368	What should be the standard of care for cancer surveillance, diagnosis of dysplasia, and the decision for colectomy in chronic inflammatory bowel disease?. 2002 , 97, 1249-1255	1
1367	Surveillance for colitis-associated cancer: we cannot stop now. 2002 , 34, 319-21	7
1366	Cancer surveillance in ulcerative colitis: critical analysis of long-term prospective programme. 2002 , 34, 339-42	21
1365	Diverticular disease as a risk factor for sigmoid colon adenomas. 2002 , 34, 635-9	36
1364	Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. 2002 , 56, 48-54	437
1363	Concepts in Surgery of the Large Intestine. 2002 , 361-382	

1362	Cancer in inflammatory bowel disease. An evidence-based analysis and guide for physicians and patients. 2002 , 31, 237-54	31
1361	Malignancies in inflammatory bowel disease: fact or fiction?. 2002 , 48-53	43
1360	Ulcerative colitis. 2002 , 359, 331-40	251
1359	Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. 2002 , 8, 10-6	244
1358	Colon cancer: detection and prevention. 2002 , 31, 565-86	9
1357	Colonic dysplasia and cancer in inflammatory bowel disease. 2002 , 12, 495-523	25
1356	Endoscopy in inflammatory bowel disease. 2002 , 31, 119-32	26
1355	Cancer prevention in patients with inflammatory bowel disease. 2002 , 31, 1133-44	31
1354	Colorectal cancer in inflammatory bowel disease: molecular and clinical features. 2002 , 31, 551-64, x	9
1353	The role of surgery in the prevention of familial cancer syndromes of the gastrointestinal tract. 2002 , 20, 91-101	2
1352	Ulcerative colitis and colon cancer: strategies for cancer prevention. 2002 , 20, 38-48	9
1351	Karzinomrisiko und Prävention bei chronisch entzündlichen Darmerkrankungen. 2002 , 18, 319-324	
1350	Colorectal cancer affects 4% of people with ulcerative colitis. 2002 , 3, 65-66	2
1349	High resolution analysis of chromosome 18 alterations in ulcerative colitis-related colorectal cancer. 2002 , 136, 129-37	8
1348	Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. 2002 , 100, 82-5	147
1347	Epigenetic control of the E-cadherin gene (CDH1) by CpG methylation in colectomy samples of patients with ulcerative colitis. 2002 , 35, 121-6	57
1346	Stratégie de dépistage des cancers colorectaux chez les sujets à risque élevé. 2002 , 32, 623-631	
1345	Cancer in Inflammatory Bowel Disease. 2002 , 5, 163-171	9

1344	Immunohistochemical expression of P53 and oncogenes in ulcerative colitis-associated colorectal carcinoma. 2002 , 26, 390-6	21
1343	Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. 2002 , 45, 615-20	131
1342	Adenocarcinoma in the residual outflow tract after incomplete excision of a failed ileoanal pouch: a late complication of unrecognized Crohn's colitis: report of a case. 2002 , 45, 1112-5	12
1341	Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. 2002 , 16, 1225-32	140
1340	Colonic malignancy arising in colitis - a single unit experience. 2002 , 4, 101-106	1
1339	Dysplasia in the ileoanal pouch. 2002 , 4, 420-9	37
1338	Chronic colitis is associated with a reduction of mucosal alkaline sphingomyelinase activity. 2002 , 8, 258-63	52
1337	Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. 2002 , 8, 356-61	56
1336	Randomized controlled trial comparing the efficacy of a video and information leaflet versus information leaflet alone on patient knowledge about surveillance and cancer risk in ulcerative colitis. 2002 , 8, 407-12	21
1335	Chromosomal instability in ulcerative colitis is related to telomere shortening. 2002 , 32, 280-4	279
1334	Dietary iron supplementation enhances DSS-induced colitis and associated colorectal carcinoma development in mice. 2002 , 47, 1266-78	130
1333	Tumors and inflammatory infiltrates: friends or foes?. 2002 , 19, 247-58	171
1332	Epidemiology and screening of colorectal cancer. 2002 , 16, 187-99	29
1331	Telomerase activity in chronic inflammatory bowel disease. 2003 , 48, 2328-32	7
1330	Is colonoscopy alone sufficient to screen for ulcerative colitis-associated colorectal carcinoma?. 2003 , 27, 611-5	26
1329	Chemoprevention of colorectal cancer in ulcerative colitis. 2003 , 18, 392-400	45
1328	Prevention by intrarectal 5-aminosalicylic acid of N-methylnitrosourea-induced colon cancer in F344 rats. 2003 , 46, 900-3	12
1327	Outcome of patients undergoing liver transplantation for primary sclerosing cholangitis. 2003 , 46, 1124-8	24

1326	Microsatellite instability and loss of heterozygosity in the nondysplastic colonic epithelium of ulcerative colitis. 2003 , 38, 734-9	7
1325	Efficacy of surveillance and molecular markers for detection of ulcerative colitis-associated colorectal neoplasia. 2003 , 38, 1117-25	14
1324	Transitioning the paediatric IBD patient to adult care. 2003 , 17, 197-212	10
1323	Surveillance colonoscopy for colitic cancer in inflammatory bowel disease. 2003 , 15, 256-262	2
1322	Rectal cancer and ulcerative colitis: does it change the therapeutic approach?. 2003 , 5, 483-5	32
1321	Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. 2003 , 18 Suppl 2, 1-5	37 ⁰
1320	Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. 2003 , 18 Suppl 2, 15-21	79
1319	Review article: colitis-associated cancer -- time for new strategies. 2003 , 18 Suppl 2, 6-9	16
1318	A new look at the anal transitional zone with reference to restorative proctocolectomy and the columnar cuff. 1998 , 85, 1517-21	66
1317	Is There Still a Role for Cyclosporine in the Treatment of Inflammatory Bowel Disease?. 2003 , 9, 202-204	
1316	Gross versus microscopic pancolitis and the occurrence of neoplasia in ulcerative colitis. 2003 , 9, 351-5	85
1315	Diagnostic problems and advances in inflammatory bowel disease. 2003 , 16, 347-58	145
1314	Alterations in the proliferating compartment of gastric mucosa during <i>Helicobacter pylori</i> infection: the putative role of epithelial cells expressing p27(kip1). 2003 , 16, 1076-85	13
1313	Radical causes of cancer. 2003 , 3, 276-85	1307
1312	Telomere dysfunction and the initiation of genome instability. 2003 , 3, 623-7	173
1311	Colorectal cancer in inflammatory bowel disease: molecular and clinical features. 2003 , 17, 525-537	
1310	[Colorectal adenocarcinoma in Crohn's disease]. 2003 , 121, 757-8	
1309	Colon cancer: detection and prevention. 2003 , 17, 553-574	

1308	Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. 2003 , 125, 1311-9	308
1307	Abnormal p53 immunohistochemistry is associated with an increased colorectal cancer-related mortality in patients with ulcerative colitis. 2003 , 98, 1423-1427	2
1306	Colorectal cancer and high grade dysplasia complicating ulcerative colitis in Italy. A retrospective co-operative IG-IBD study. 2003 , 35, 628-34	8
1305	Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. 2003 , 124, 57-70	148
1304	The color of dysplasia in ulcerative colitis. 2003 , 124, 1135-8	39
1303	Cytology and image cytometry after colonic lavage: a complementary diagnostic tool in patients with ulcerative colitis. 2003 , 35, 24-31	1
1302	RELP, a novel human REG-like protein with up-regulated expression in inflammatory and metaplastic gastrointestinal mucosa. 2003 , 163, 11-20	45
1301	DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free. 2003 , 162, 665-72	64
1300	Primary colorectal T-cell lymphoma. 2003 , 38, 376-84	11
1299	Regulation of leukotriene-dependent induction of cyclooxygenase-2 and Bcl-2. 2003 , 302, 330-5	23
1298	Anorectal and Colon Diseases. 2003 ,	13
1297	Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. 2003 , 197, 1213-9	144
1296	Hepatocyte growth factor facilitates colonic mucosal repair in experimental ulcerative colitis in rats. 2003 , 307, 146-51	86
1295	Inflammatory Bowel Disease Principles and Practice. 2003 , 20, 339-382	
1294	Multiple microcarcinoids in a patient with long standing ulcerative colitis. 2003 , 56, 963-5	23
1293	Cigarette smoke exposure increases ulcerative colitis-associated colonic adenoma formation in mice. 2003 , 24, 1407-13	49
1292	Abnormal p53 immunohistochemistry is associated with an increased colorectal cancer-related mortality in patients with ulcerative colitis. 2003 , 98, 1423-7	19
1291	Earlier surveillance colonoscopy programme improves survival in patients with ulcerative colitis associated colorectal cancer: results of a 23-year surveillance programme in the Japanese population. 2003 , 89, 1232-6	103

1290	Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer?. 2003 , 98, 2784-8	90
1289	Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow. 2003 , 98, 1682-7	40
1288	Chromoscopy might improve diagnostic accuracy in cancer surveillance for ulcerative colitis. 2003 , 98, 1827-33	113
1287	Leukotriene D4 mediates survival and proliferation via separate but parallel pathways in the human intestinal epithelial cell line Int 407. 2003 , 278, 45577-85	46
1286	Prevalence and management of inflammatory bowel disease: a cross-sectional study from central England. 2003 , 15, 1275-80	81
1285	Cost-effectiveness of colorectal cancer surveillance in ulcerative colitis. 2003 , 17-21	12
1284	The histologic diagnosis of dysplasia, dysplasia-associated lesion or mass, and adenoma: a pathologist's perspective. 2003 , 36, S63-9; discussion S94-6	18
1283	Dysplasia and colorectal cancer in Crohn's disease. 2003 , 36, S75-8; discussion S94-6	22
1282	Does monitoring prevent cancer in inflammatory bowel disease?. 2003 , 36, S79-83; discussion S94-6	15
1281	The anti-apoptotic effect of leukotriene D4 involves the prevention of caspase 8 activation and Bid cleavage. 2003 , 371, 115-24	20
1280	[Ulcerative colitis. Cancer prevention]. 2004 , 42, 1014-8	2
1279	[S3-Guidelines Conference "Colorectal Carcinoma" 2004]. 2004 , 42, 1129-77	114
1278	Ulcerative colitis: the fate of the retained rectum. 2004 , 17, 29-34	9
1277	Kolitis-assoziierte Karzinome, Prävention und Früherkennung. 2004 , 39, 281-289	
1276	Divergent patterns of total and cancer mortality in ulcerative colitis and Crohn's disease patients: the Florence IBD study 1978-2001. 2004 , 53, 1309-13	57
1275	Development of colonic neoplasia in p53 deficient mice with experimental colitis induced by dextran sulphate sodium. 2004 , 53, 710-6	52
1274	Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. 2004 , 53, 1813-6	301
1273	Aetiology of colorectal cancer and relevance of monogenic inheritance. 2004 , 53, 115-22	25

1272	Protagonist: Early surgical intervention in ulcerative colitis. 2004 , 53, 306-7	7
1271	Expression of CXCL16 in human rectal cancer. 2004 , 14, 65	3
1270	Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence for involvement of the transcription factor Egr-1. 2004 , 279, 12647-58	104
1269	A BALANCING VIEW: Dysplasia surveillance in ulcerative colitis--sorting the pro from the con. 2004 , 99, 1636-7	8
1268	CON: surveillance for ulcerative colitis-associated cancer: time to change the endoscopy and the microscopy. 2004 , 99, 1633-6	11
1267	PRO: Endoscopic surveillance minimizes the risk of cancer. 2004 , 99, 1631-3	11
1266	Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. 2004 , 19, 287-93	170
1265	Adenomatous colonic polyps are rare in ulcerative colitis. 2004 , 19, 879-87	11
1264	Review article: the chemoprevention of colorectal carcinoma. 2004 , 20 Suppl 4, 31-5	11
1263	Review article: colorectal carcinoma and inflammatory bowel disease. 2004 , 20 Suppl 4, 24-30	76
1262	Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial. 2004 , 20, 1353-63	22
1261	Tissue repair and stem cell renewal in carcinogenesis. 2004 , 432, 324-31	995
1260	Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease. 2004 , 10 Suppl 2, S2-10	26
1259	Anxiety, functional health status, and coping ability in patients with ulcerative colitis who are undergoing colonoscopic surveillance. 2004 , 10, 612-7	7
1258	Difference in Ulex europaeus agglutinin I-binding activity of decay-accelerating factor detected in the stools of patients with colorectal cancer and ulcerative colitis. 2004 , 143, 169-74	4
1257	[Precancerous lesions and IBD endoscopic features]. 2004 , 28, D149-56	1
1256	Colonic surveillance by CT colonography using axial images only. 2004 , 14, 763-7	15
1255	A beginner's guide to NF-kappaB signaling pathways. 2004 , 1030, 1-13	85

1254	Dysplasia in ulcerative colitis--clinical consequences?. 2004 , 389, 354-60	13
1253	A high degree of aneuploidy, loss of p53 gene, and low soluble p53 protein serum levels are detected in ulcerative colitis patients. 2004 , 47, 304-13	12
1252	Surveillance for dysplasia in patients with inflammatory bowel disease: a national survey of colonoscopic practice in New Zealand. 2004 , 47, 314-22	38
1251	[When is ileocolonoscopy indicated in chronic inflammatory intestinal diseases?]. 2004 , 154, 92-4	
1250	La surveillance coloscopique classique de la colite ulcéreuse (CU) en vaut-elle la peine ?. 2004 , 34, 179-188	
1249	Chimio-prévention du cancer colorectal dans les maladies inflammatoires intestinales chroniques. Quels sont les médicaments proposés ?. 2004 , 34, 199-213	
1248	Dysplasie (néoplasie intraépithéliale) et maladies inflammatoires chroniques idiopathiques du côlon (MICI). 2004 , 34, 215-229	3
1247	Histoire naturelle et facteurs de risque du cancer colorectal au cours des maladies inflammatoires intestinales. 2004 , 34, 231-236	
1246	Specificities of inflammatory bowel disease in childhood. 2004 , 18, 509-23	257
1245	Simultaneous detection of synchronous colonic and biliary carcinoma by abdominal ultrasonography in two patients with ulcerative colitis. 2004 , 49, 1922-9	4
1244	Morbus-Crohn-assoziierte kolorektale Karzinome. 2004 , 26, 134	
1243	Detection of occult tumour cells in lymph nodes of colorectal cancer patients using real-time quantitative RT-PCR for CEA and CK20 mRNAs. 2004 , 111, 101-10	28
1242	Epidemiology of IBD during the twentieth century: an integrated view. 2004 , 18, 463-79	121
1241	Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. 2004 , 2, 534-41	210
1240	Guidelines for the management of inflammatory bowel disease in adults. 2004 , 53 Suppl 5, V1-16	774
1239	[Clinical guidelines for the prevention of colorectal cancer]. 2004 , 27, 573-634	5
1238	Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. 2004 , 126, 451-9	961
1237	Endoscopy in inflammatory bowel diseases. 2004 , 126, 1561-73	100

1236	Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. 2004 , 126, 1634-48	355
1235	Ulcerative colitis with low-grade dysplasia. 2004 , 127, 950-6	34
1234	Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. 2004 , 2, 1088-95	229
1233	The role and importance of endoscopic mucosal healing in ulcerative colitis. 2004 , 6, 144-153	1
1232	Magnification endoscopy, chromoendoscopy and other novel techniques in evaluation of patients with IBD. 2004 , 6, 182-188	4
1231	Inflammatory mechanisms contributing to pancreatic cancer development. 2004 , 239, 763-9; discussion 769-71	126
1230	Colorectal cancer in inflammatory bowel disease. 2004 , 20, 43-8	27
1229	Hereditary pancreatitis as the premalignant disease: a Japanese case of pancreatic cancer involving the SPINK1 gene mutation N34S. 2004 , 28, 305-10	27
1228	Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. 2004 , CD000279	34
1227	Folate and prevention of colorectal cancer in ulcerative colitis. 2005 , 14, 395-8	13
1226	Dysplasia in inflammatory bowel disease: clinical pathology and current surveillance methods. 2003 , 719-729	
1225	Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. 2005 , 28, 187-96	210
1224	SUBTLE VILLOUS CHANGES DETECTED AT ENDOSCOPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. 2005 , 17, S34-S39	3
1223	Risk of colorectal cancer in ulcerative colitis in India. 2005 , 20, 705-9	38
1222	Inflammatory bowel disease in Iran: a review of 457 cases. 2005 , 20, 1691-5	99
1221	Lymphocyte telomere dynamics and telomerase activity in inflammatory bowel disease: effect of drugs and smoking. 2005 , 21, 121-31	15
1220	Accumulation of mitochondrial DNA mutation with colorectal carcinogenesis in ulcerative colitis. 2005 , 93, 331-7	54
1219	Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease. 2005 , 11, 428-34	40

1218	Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. 2005 , 11, 314-21	472
1217	Optimizing therapy in patients with pancolitis. 2005 , 11, 937-46	6
1216	Who takes the lead in the development of ulcerative colitis-associated colorectal cancers: mutator, suppressor, or methylator pathway?. 2005 , 162, 68-73	20
1215	Characterization of genomic instability in ulcerative colitis neoplasia leads to discovery of putative tumor suppressor regions. 2005 , 162, 99-106	19
1214	Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. 2005 , 5, 46	104
1213	Mutations of the BRAF gene in ulcerative colitis-related colorectal carcinoma. 2005 , 115, 673-7	35
1212	Colorectal cancer surveillance in patients with ulcerative colitis. 1994 , 81, 689-91	51
1211	Diarrhea in liver transplant recipients: etiology and management. 2005 , 11, 881-90	126
1210	[S3 guideline by the German Society of Digestive and Metabolic Diseases and the Competence Network of Chronic Inflammatory Bowel diseases on diagnosis and therapy of ulcerative colitis. An update]. 2005 , 100, 43-50	3
1209	Crohn's colitis presenting with node-negative colon cancer and liver metastasis after therapy with infliximab: report of two cases. 2005 , 48, 1651-5	10
1208	Epidemiologie, Risikofaktoren und Pathologie des Rektumkarzinoms. 2005 , 11, 807-813	
1207	Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. 2005 , 19 Suppl A, 5A-36A	2167
1206	Activation of cPLA2 is required for leukotriene D4-induced proliferation in colon cancer cells. 2005 , 26, 1988-98	35
1205	Ulcerative colitis, colorectal cancer and colonoscopic surveillance. 2005 , 40, 881-5	10
1204	Colon stenosis in a patient with ulcerative colitis as a manifestation of mixed müllerian tumor of the peritoneum. 2005 , 40, 1251-4	2
1203	The pro-inflammatory mediator leukotriene D4 induces phosphatidylinositol 3-kinase and Rac-dependent migration of intestinal epithelial cells. 2005 , 280, 13538-44	52
1202	Prediction of colorectal neoplasia by quantitative methylation analysis of estrogen receptor gene in nonneoplastic epithelium from patients with ulcerative colitis. 2005 , 11, 8880-5	48
1201	Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice. 2006 , 27, 162-9	157

1200	Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. 2005 , 37, 1186-92	234
1199	Colorectal cancer: epidemiology, risk factors, and health services. 2005 , 18, 133-40	80
1198	[S3-guideline conference "Colorectal Cancer" 2004]. 2005 , 130 Suppl 1, S5-53	17
1197	Chronic inflammation promotes retinoblastoma protein hyperphosphorylation and E2F1 activation. 2005 , 65, 9132-6	43
1196	Methylation of the oestrogen receptor gene in non-neoplastic epithelium as a marker of colorectal neoplasia risk in longstanding and extensive ulcerative colitis. 2005 , 54, 1287-92	49
1195	Infection, inflammation, and gastrointestinal cancer. 2005 , 54, 1321-31	70
1194	Preventing neoplastic progression in ulcerative colitis. 2005 , 39, S66-9	14
1193	Human AP endonuclease suppresses DNA mismatch repair activity leading to microsatellite instability. 2005 , 33, 5073-81	10
1192	Prevenci3 primaria y clasificaci3 del riesgo del c3ncer colorrectal. 2005 , 12, 347-360	
1191	Leukotriene D4 activates distinct G-proteins in intestinal epithelial cells to regulate stress fibre formation and to generate intracellular Ca2+ mobilisation and ERK1/2 activation. 2005 , 302, 31-9	19
1190	Inflammation's role in rectal cancer following prostate radiotherapy, and emerging evidence for a protective role for balsalazide. 2005 , 129, 770-2	3
1189	Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. 2005 , 3, 1015-21	92
1188	Inflammatory bowel disease-related dysplasia and cancer: A referral center study in northwestern Greece. 2005 , 16, 170-175	13
1187	The variable risk of colorectal cancer in patients with inflammatory bowel disease. 2005 , 16, 139-140	2
1186	Colorectal cancer in patients with inflammatory bowel disease. 2005 , 4, 313-9	45
1185	Molecular phenotype of inflammatory bowel disease-associated neoplasms with microsatellite instability. 2005 , 129, 74-85	59
1184	Inflammation's Role in Rectal Cancer Following Prostate Radiotherapy, and Emerging Evidence for a Protective Role for Balsalazide. 2005 , 129, 770-772	3
1183	Surveillance for cancer and dysplasia in inflammatory bowel disease. 2006 , 35, 581-604	36

1182	Mortality in COPD: Role of comorbidities. 2006 , 28, 1245-57	689
1181	Chemoprevention for colon cancer: new opportunities, fact or fiction?. 2006 , 158-64	14
1180	Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease. 2006 , 35, 675-712	38
1179	Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. 2006 , 35, 517-31	88
1178	Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. 2006 , 4, 1346-50	99
1177	Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. 2006 , 130, 1030-8	514
1176	Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. 2006 , 130, 1039-46	390
1175	When is too much enough?. 2006 , 130, 1352-4	4
1174	The changing face of colorectal cancer in inflammatory bowel disease: progress at last!. 2006 , 130, 1350-2	30
1173	Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. 2006 , 130, 1941-9	320
1172	[Cytokines in the pathogenesis of inflammatory bowel diseases]. 2006 , 127, 145-52	10
1171	Concepts in Surgery of the Large Intestine. 2006 , 3-24	
1170	Dysplasia in Inflammatory Bowel Disease: from Genetics to Treatment. 2006 , 35-44	1
1169	IBD: Cancer Risk and Surveillance. 2006 , 45-49	
1168	Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. 2006 , CD000279	125
1167	Increased risk of breast cancer in first-degree relatives of Crohn's disease patients. An IG-IBD study. 2006 , 38, 18-23	14
1166	Fecal Adnab-9 binding as a risk marker for colorectal neoplasia. 2006 , 235, 48-52	3
1165	Should we screen for colorectal cancer in liver transplantation?. 2006 , 44, 32-8	13

1164	Follow-up of patients with ileo-anal pouch following stoma reversal. 2006 , 4, 16-23	5
1163	Screening for colon cancer. 2006 , 6, S13-21	7
1162	The approach to dysplasia surveillance in inflammatory bowel disease. 2006 , 20, 251-3	5
1161	Surveillance Colonoscopy in Uc: Alternatives and Ways to Improve Outcome. 15-17	
1160	. 2006 ,	0
1159	Colitis-Associated Cancer: What's the Risk to Your Patients?. 185-188	
1158	Cancer du cŕon. 2006 , 1, 1-18	
1157	Optimizing quality of outpatient care for patients with inflammatory bowel disease: the importance of specialist clinics. 2006 , 18, 249-53	54
1156	Chromosomal and microsatellite instability of adenocarcinomas and dysplastic lesions (DALM) in ulcerative colitis. 2006 , 15, 216-22	24
1155	Characterization of tumour-infiltrating lymphocytes and apoptosis in colitis-associated neoplasia: comparison with sporadic colorectal cancer. 2006 , 208, 381-7	14
1154	Loss of transgelin in repeated bouts of ulcerative colitis-induced colon carcinogenesis. 2006 , 6, 1158-65	34
1153	Induction of squamous cell carcinoma of forestomach in diabetic rats by single alloxan treatment. 2006 , 97, 1023-30	16
1152	Systematic review: managing anaemia in Crohn's disease. 2006 , 24, 1507-23	216
1151	Review article: Indeterminate colitis--definition, diagnosis and management. 2007 , 25, 13-7	24
1150	Risk factors for colorectal cancer in Crohn's colitis: a case-control study. 2006 , 12, 491-6	41
1149	Oral mesalamine and clinical remission are associated with a decrease in the extent of long-standing ulcerative colitis. 2006 , 12, 537-42	11
1148	Regulation of apoptosis during homeostasis and disease in the intestinal epithelium. 2006 , 12, 413-24	130
1147	Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. 2006 , 12, 205-11	159

1146	DNA hypermethylation in colorectal neoplasms and inflammatory bowel disease: a mini review. 2006 , 14, 204-6	13
1145	Risk factors and indications for colectomy in ulcerative colitis patients are different according to patient's clinical background. 2006 , 49, 1307-15	27
1144	Genomic analysis of a case of multifocal adenocarcinoma in ulcerative colitis. 2006 , 449, 716-21	2
1143	Colorectal cancer in inflammatory bowel disease: molecular and clinical considerations. 2006 , 9, 211-20	17
1142	Genetics of inflammatory bowel disease and associated cancers. 2006 , 2, 191-199	1
1141	Place de l'endoscopie dans le dépistage du cancer colique au cours des MICI. 2006 , 36, 701-711	
1140	Induction of inflammatory bowel disease accelerates adenoma formation in Min +/- mice. 2006 , 139, 782-8	16
1139	Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells. 2006 , 97, 709-23	120
1138	Alpha2beta1 integrin signalling enhances cyclooxygenase-2 expression in intestinal epithelial cells. 2006 , 209, 950-8	22
1137	Dietary administration with prenyloxycoumarins, auraptene and collinin, inhibits colitis-related colon carcinogenesis in mice. 2006 , 118, 2936-42	87
1136	Heterogeneous microsatellite instability observed within epithelium of ulcerative colitis. 2006 , 119, 2513-9	10
1135	[Aminosalicylates and steroids in the treatment of chronic inflammatory bowel diseases--consensus paper of the Working Group for Chronic Inflammatory Bowel Diseases of the OGGH]. 2006 , 44, 525-38; discussion 539	5
1134	[Endoscopy in IBD. A Consensus Report of the IBD Working of the Austrian Association of Gastroenterology and Hepatology]. 2006 , 44, 1183-92	3
1133	Induction of inducible nitric oxide synthase: a protective mechanism in colitis-induced adenocarcinoma. 2007 , 28, 1122-30	29
1132	Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. 2006 , 26, 31-41	174
1131	Endoscopic Oncology. 2006 ,	
1130	Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha. 2006 , 290, G361-8	63
1129	Perspectives on pulmonary inflammation and lung cancer risk in cigarette smokers. 2006 , 18, 667-77	87

1128	Principles of Surgical Therapy in Oncology. 2006 , 58-72	4
1127	Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study. 2006 , 15, 690-5	79
1126	Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. 2006 , 66, 11580-4	374
1125	Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates. 2006 , 73, 11-9	38
1124	Elevated anal squamous cell carcinoma risk associated with benign inflammatory anal lesions. 2006 , 55, 703-7	17
1123	Increased etheno-DNA adducts in affected tissues of patients suffering from Crohn's disease, ulcerative colitis, and chronic pancreatitis. 2006 , 8, 1003-10	85
1122	Novel aspects of oxidative stress-associated carcinogenesis. 2006 , 8, 1373-7	80
1121	Survival after colorectal cancer in patients with ulcerative colitis: a nationwide population-based Danish study. 2006 , 101, 1283-7	76
1120	Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. 2007 , 102, 829-36	114
1119	Techniques for targeting screening in ulcerative colitis. 2007 , 83, 451-60	10
1118	RAGE and RAGE ligands in cancer. 2007 , 7, 777-89	151
1117	Microsatellite instability in long-standing ulcerative colitis. 2007 , 42, 586-91	12
1116	Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence. 2007 , 56 Suppl 1, 1-113	89
1115	Involvement of the serrated neoplasia pathway in inflammatory bowel disease-related colorectal oncogenesis. 2007 , 18, 1093	1
1114	[Surveillance colonoscopy in ulcerative colitis patients in Germany]. 2007 , 45, 325-31	19
1113	Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. 2007 , 41, 21-8	70
1112	Loss of p53 enhances the induction of colitis-associated neoplasia by dextran sulfate sodium. 2007 , 28, 2375-81	43
1111	An increased expression of cysteinyl leukotriene 2 receptor in colorectal adenocarcinomas correlates with high differentiation. 2007 , 67, 9190-8	34

1110 Colorectal Cancer: Epidemiology, Etiology, and Molecular Basis. **2007**, 335-352

1109 Chronic periodontitis and the risk of tongue cancer. **2007**, 133, 450-4 121

1108 Ursodeoxycholic acid versus sulfasalazine in colitis-related colon carcinogenesis in mice. **2007**, 13, 2519-25 41

1107 Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study. **2007**, 75, 113-21 41

1106 Colon cancer screening in women. **2007**, 3, 163-72 2

1105 Increased proliferation of middle to distal colonic cells during colorectal carcinogenesis in experimental murine ulcerative colitis. **2007**, 18, 1457 1

1104 & 18: Perianal and Anal Canal Neoplasms /. **2007**, 393-414 1

1103 Part III: Colorectal Disorders. **2007**, 439-474

1102 TLR4 signalling in the intestine in health and disease. **2007**, 35, 1473-8 127

1101 Malignant Neoplasms of the Rectum. **2007**, 207-304

1100 Phytochemicals and cancer. **2007**, 66, 207-15 127

1099 Wnt pathway-related gene expression during malignant progression in ulcerative colitis. **2007**, 109, 266-72 37

1098 Cancer and pediatric inflammatory bowel disease. **2007**, 16, 205-13 16

1097 A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. **2007**, 132, 763-86 724

1096 Colorectal Cancer. **2007**, 1

1095 Interaction of cigarette smoking with cyclooxygenase-2 on ulcerative colitis-associated neoplasia in mice. **2007**, 25, 750-7 7

1094 Neoplastic precursor lesions related to the development of cancer in inflammatory bowel disease. **2007**, 36, 901-26, vii-viii 12

1093 Endoscopy/surveillance in inflammatory bowel disease. **2007**, 87, 743-62 15

1092	Pathophysiology of inflammatory bowel disease: an overview. 2007 , 87, 575-85	81
1091	Associated neoplastic disease in inflammatory bowel disease. 2007 , 87, 659-72	7
1090	5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. 2007 , 132, 221-35	62
1089	Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias. 2007 , 132, 1254-60	77
1088	Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. 2007 , 132, 874-82	454
1087	Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. 2007 , 133, 1099-105; quiz 1340-1	560
1086	Hospitalization-based major comorbidity of inflammatory bowel disease in Canada. 2007 , 21, 507-11	38
1085	The role of leukotriene receptor signaling in inflammation and cancer. 2007 , 7, 1413-21	30
1084	Signaling Chains. 2007 , 189-214	
1083	Tumor-Associated Myeloid-Derived Suppressor Cells. 2007 , 309-331	1
1082	Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts. 2007 , 13, 1293-8	15
1081	An expensive and empty ritual: the continued use of random biopsy technique for detecting dysplasia in patients with colitis--pro. 2007 , 13, 1271-2	3
1080	Population-based analysis of practices and costs of surveillance for colonic dysplasia in patients with primary sclerosing cholangitis and colitis. 2007 , 13, 1401-7	24
1079	Controversies in Pediatric Inflammatory Bowel Disease. 2007 , 4, 203-227	5
1078	Risk factors and distinguishing features of cancer in IBD. 2007 , 4, 235-243	5
1077	Colorectal carcinoma development in inducible nitric oxide synthase-deficient mice with dextran sulfate sodium-induced ulcerative colitis. 2007 , 46, 341-53	34
1076	Hypermethylation of p14 (ARF) may be predictive of colitic cancer in patients with ulcerative colitis. 2007 , 50, 1384-92	39
1075	Therapeutic effect of nimesulide on colorectal carcinogenesis in experimental murine ulcerative colitis. 2007 , 22, 1474-81	6

1074	Colorectal neoplasia in Crohn's colitis: a retrospective comparative study with ulcerative colitis. 2007 , 50, 574-83	52
1073	Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. 2007 , 25, 657-68	201
1072	Dextran sulfate sodium-induced colitis-associated neoplasia: a promising model for the development of chemopreventive interventions. 2007 , 28, 1450-9	138
1071	Ulcerative colitis. 2007 , 35, 277-282	5
1070	Neonatal co-infection with helicobacter species markedly accelerates the development of inflammation-associated colonic neoplasia in IL-10(-/-) mice. 2007 , 12, 598-604	30
1069	Inflammatory bowel disease: the problems of dysplasia and surveillance. 2007 , 11, 299-309	6
1068	Differential roles of the SPINK1 gene mutations in alcoholic and nonalcoholic chronic pancreatitis. 2007 , 42 Suppl 17, 135-40	22
1067	Intestinal cancer in patients with Crohn's disease. 2007 , 22, 411-7	14
1066	The proinflammatory CXC-chemokines GRO-alpha/CXCL1 and MIG/CXCL9 are concomitantly expressed in ulcerative colitis and decrease during treatment with topical corticosteroids. 2007 , 22, 1421-7	56
1065	p53 mutations are associated with dysplasia and progression of dysplasia in patients with Crohn's disease. 2008 , 53, 474-80	19
1064	Epigenetic regulation of WNT signaling pathway genes in inflammatory bowel disease (IBD) associated neoplasia. 2008 , 12, 1745-53	66
1063	Ulcerative colitis-associated colorectal cancer is frequently associated with the microsatellite instability pathway. 2008 , 51, 1387-94	38
1062	Importance of postpolypectomy surveillance and postpolypectomy compliance to follow-up screening--review of literature. 2008 , 23, 453-9	28
1061	Primary CD56+ NK/T-cell lymphoma of the rectum accompanied with refractory ulcerative colitis. 2008 , 43, 576-80	10
1060	Macrophage activation by endogenous danger signals. 2008 , 214, 161-78	384
1059	Increased susceptibility of chronic ulcerative colitis-induced carcinoma development in DNA repair enzyme Ogg1 deficient mice. 2008 , 47, 638-46	46
1058	Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. 2008 , 14, 265-74	58
1057	Association of hyperhomocysteinemia and folate deficiency with colon tumors in patients with inflammatory bowel disease. 2008 , 14, 242-8	33

1056	Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. 2008 , 14, 1000-11	94
1055	Synchronous multifocal colorectal carcinoma in a patient with delayed diagnosis of ulcerative pancolitis. 2008 , 204, 905-10	8
1054	Diverticulosis and diverticulitis form no risk for polyps and colorectal neoplasia in 4,241 colonoscopies. 2008 , 23, 979-84	64
1053	What is the prognosis of ulcerative colitis?. 2008 , 14 Suppl 2, S52-3	5
1052	How often do IBD patients require resection of their intestine?. 2008 , 14 Suppl 2, S68-9	16
1051	Leukotriene D(4) induces AP-1 but not NFkappaB signaling in intestinal epithelial cells. 2008 , 85, 100-6	3
1050	Chronic inflammatory changes in the anal transition zone after stapled ileal pouch-anal anastomosis: is mucosectomy a superior alternative?. 2008 , 144, 533-7; discussion 537-9	25
1049	Cancer in inflammatory bowel disease. 2008 , 14, 378-89	241
1048	Principles of Cancer Surgery. 2008 , 1965-1984	
1047	Collision tumor of the large bowel in the context of advanced pregnancy and ulcerative colitis. 2008 , 7, 402-5	7
1046	Tumor necrosis factor-alpha polymorphisms in ulcerative colitis-associated colorectal cancer. 2008 , 103, 407-15	49
1045	European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. 2008 , 2, 1-23	402
1044	European evidence-based Consensus on the management of ulcerative colitis: Special situations. 2008 , 2, 63-92	165
1043	Effects of black soybean [Glycine max (L.) Merr.] seed coats and its anthocyanidins on colonic inflammation and cell proliferation in vitro and in vivo. 2008 , 56, 8427-33	67
1042	Oxidative stress in Fanconi anemia hematopoiesis and disease progression. 2008 , 10, 1909-21	94
1041	The challenges in primary sclerosing cholangitis--aetiopathogenesis, autoimmunity, management and malignancy. 2008 , 48 Suppl 1, S38-57	108
1040	Regulation of the eicosanoid pathway by tumour necrosis factor alpha and leukotriene D4 in intestinal epithelial cells. 2008 , 79, 223-31	15
1039	Genomic biomarkers to improve ulcerative colitis neoplasia surveillance. 2008 , 173, 1853-60	23

1038	Indicaciones de la endoscopia intestinal y de la toma de biopsias en la enfermedad inflamatoria intestinal. 2008 , 10, 334-337	
1037	Severe complications of inflammatory bowel disease. 2008 , 92, 671-86, ix	11
1036	[Chronic inflammatory bowel disease: case no. 6]. 2008 , 28, 211-4	
1035	Is dysplasia visible during surveillance colonoscopy in patients with ulcerative colitis?. 2008 , 43, 698-703	51
1034	High frequency of early colorectal cancer in inflammatory bowel disease. 2008 , 57, 1246-51	137
1033	The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. 2008 , 68, 10060-7	185
1032	Limits of diagnosis and molecular markers for early detection of ulcerative colitis-associated colorectal neoplasia. 2008 , 77 Suppl 1, 2-12	23
1031	Colon cancer surveillance in inflammatory bowel disease patients: current and emerging practices. 2008 , 2, 817-25	8
1030	Risk factors associated with small bowel adenocarcinoma in Crohn's disease: a case-control study. 2008 , 103, 1730-6	52
1029	Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. 2008 , 103, 2342-9	247
1028	The short chain fatty acid butyrate induces promoter demethylation and reactivation of RARbeta2 in colon cancer cells. 2008 , 60, 692-702	49
1027	Citrus compounds inhibit inflammation- and obesity-related colon carcinogenesis in mice. 2008 , 60 Suppl 1, 70-80	48
1026	A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia. 2008 , 8, 237-47	33
1025	Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer. 2008 , 1, 187-91	240
1024	Myeloperoxidase-positive cell infiltration in colorectal carcinogenesis as indicator of colorectal cancer risk. 2008 , 17, 2291-7	73
1023	15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation. 2008 , 22, 1981-92	19
1022	Inciting inflammation: the RAGE about tumor promotion. 2008 , 205, 267-70	39
1021	Dietary cancer chemopreventive agents - targeting inflammation and Nrf2 signaling pathway. 2008 , 74, 1540-7	53

1020	Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. 2008 , 103, 111-9	186
1019	How often do IBD patients require resection of their intestine?. 2008 , 14, S68-S69	2
1018	Incidence and prevalence of inflammatory bowel disease in children in south-western Sweden. 1994 , 83, 640-5	46
1017	Synchronous colitic cancers and microcarcinoids in a patient with long-standing and extensive ulcerative colitis: a case report and review of the literature. 2008 , 18, 304-7	2
1016	What is the prognosis of ulcerative colitis?. 2008 , 14, S52-S53	
1015	Mucosal T cell proliferation and apoptosis in inflammatory bowel disease. 2008 , 9, 381-7	40
1014	Early onset of ulcerative colitis: long-term follow-up with special reference to colorectal cancer and primary sclerosing cholangitis. 2008 , 46, 534-8	21
1013	Involvement of Smad3 phosphoisoform-mediated signaling in the development of colonic cancer in IL-10-deficient mice. 2008 ,	
1012	The role of thrombospondin 1 on intestinal inflammation and carcinogenesis. 2008 , 3, 171-8	18
1011	A super "lead-pipe" colon: radio-pathological correlation of long-standing ulcerative colitis. 2008 , 12, 70	1
1010	COLORECTAL CANCER IN ULCERATIVE COLITIS. 2008 , 1509-1535	
1009	Colorectal cancer in inflammatory bowel disease. 2008 , 2, 61-73	65
1008	Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. 2008 , 14, 3937-47	280
1007	Colorectal cancer and dysplasia in inflammatory bowel disease. 2008 , 14, 2662-9	105
1006	Epithelial Neoplasms of the Large Intestine. 2009 , 597-637	5
1005	Large Intestine (Colon). 2009 , 755-836	1
1004	Inflammatory Disorders of the Large Intestine. 2009 , 355-394	3
1003	Adherence to guidelines for surveillance colonoscopy in patients with ulcerative colitis at a Canadian quaternary care hospital. 2009 , 23, 613-7	22

1002	CD47 regulates collagen I-induced cyclooxygenase-2 expression and intestinal epithelial cell migration. 2009 , 4, e6371	21
1001	Intestinal mucosal inflammation leads to systemic genotoxicity in mice. 2009 , 69, 4827-34	85
1000	Nitric oxide and TNF-alpha trigger colonic inflammation and carcinogenesis in Helicobacter hepaticus-infected, Rag2-deficient mice. 2009 , 106, 1027-32	146
999	Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. 2009 , 15, 1931-9	116
998	Endoscopic and pathological aspects of colitis-associated dysplasia. 2009 , 6, 671-8	21
997	Colorectal carcinogenesis: Review of human and experimental animal studies. 2009 , 8, 5	201
996	Mesalamine suppresses the expression of TC22, a novel tropomyosin isoform associated with colonic neoplasia. 2009 , 76, 183-91	9
995	More damaging than we think: systemic effects of intestinal inflammation. 2009 , 8, 2482-3	10
994	Malignant transformation in inflammatory bowel disease - surveillance guide. 2009 , 27, 584-90	7
993	Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. 2009 , 44, 46-55	68
992	MHC Class II alleles in ulcerative colitis-associated colorectal cancer. 2009 , 58, 1226-33	23
991	Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. 2009 , 296, G850-9	109
990	Genetic risk for colitis-associated colorectal cancer. 2009 , 58, 1177-9	2
989	Kalonji (Thymoquinone). 2009 , 257-280	1
988	Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. 2009 , 15, 5878-87	158
987	[Colorectal cancer: from diagnosis to screening]. 2009 , 33, 660-71	6
986	Colon cancer in inflammatory bowel disease: recent trends, questions and answers. 2009 , 33 Suppl 3, S190-201	20
985	Two distinct groups of colorectal cancer in inflammatory bowel disease. 2009 , 15, 9-16	28

984	Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon. 2009 , 15, 630-8	97
983	Cancer risk among patients with cystic fibrosis and their first-degree relatives. 2009 , 125, 2953-6	37
982	Analysis of mutations in TP53, APC, K-ras, and DCC genes in the non-dysplastic mucosa of patients with inflammatory bowel disease. 2009 , 24, 1141-8	6
981	Inflammatory bowel disease and colorectal cancer: What is new?. 2009 , 5, 35-39	
980	Altered expression of MUTYH and an increase in 8-hydroxydeoxyguanosine are early events in ulcerative colitis-associated carcinogenesis. 2009 , 219, 77-86	29
979	Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes?. 2009 , 29, 459-69	47
978	Proctocolectomy for colon cancer associated with ulcerative colitis a few months after living donor liver transplantation for primary sclerosing cholangitis: report of a case. 2009 , 39, 59-63	8
977	Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. 2009 , 6, 297-305	211
976	Is complement good or bad for cancer patients? A new perspective on an old dilemma. 2009 , 30, 286-92	109
975	Rationale for cancer prevention strategies in high-risk ulcerative colitis. 2009 , 7, 96-100	6
974	Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. 2009 , 136, 1561-7; quiz 1818-9	187
973	Is ulcerative colitis proctitis associated with an increased risk of colorectal cancer?. 2009 , 137, 1857-8; author reply 1858	2
972	Reply. 2009 , 137, 1858	1
971	Beta-catenin is involved in alterations in mitochondrial activity in non-transformed intestinal epithelial and colon cancer cells. 2009 , 101, 1596-605	12
970	Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells. 2009 , 15, 5249-59	64
969	Inflammation and cancer. Methods and protocols. Volume 1: Experimental models and practical approaches. Preface. 2009 , 511, v-viii	2
968	The future of molecular approaches to inflammatory bowel disease. 2009 , 13, 217-23	1
967	Forensic STR analysis reveals DNA contamination previously undetected during clinical analysis of chronically inflamed tissues. 2009 , 2, 14-16	2

966	Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. 2009 , 33, 854-62	145
965	Paediatric inflammatory bowel disease during a 44-year period in Copenhagen County: occurrence, course and prognosis—a population-based study from the Danish Crohn Colitis Database. 2009 , 21, 1291-301	36
964	Épidémiologie des cancers du tube digestif. 2009 , 4, 1-8	1
963	Clinical characteristics of inflammatory bowel disease in Turkey: a multicenter epidemiologic survey. 2009 , 43, 51-7	42
962	Epstein-Barr virus-associated lymphoproliferative disorder in Crohn disease treated with azathioprine. 2010 , 51, 229-31	6
961	Colorectal cancer complicating inflammatory bowel disease: similarities and differences between Crohn's and ulcerative colitis based on three decades of experience. 2010 , 252, 330-5	73
960	Tumor necrosis factor alpha induces p53 up-regulated modulator of apoptosis expression in colorectal cancer cell lines. 2010 , 53, 257-63	14
959	R-etodolac induces E-cadherin and suppresses colitis-related mouse colon tumorigenesis. 2010 , 24, 1487-92	13
958	Immunophysiological mechanisms of the origin and maintenance of tumor growth in humans. 2010 , 36, 373-381	2
957	Homeostasis of adult human stem cells and carcinogenesis. 2010 , 36, 621-628	
956	Prevalence of metabolic syndrome is comparable between inflammatory bowel disease patients and the general population. 2010 , 45, 1008-13	24
955	R72P polymorphism of TP53 in ulcerative colitis patients is associated with the incidence of colectomy, use of steroids and the presence of a positive family history. 2010 , 16, 563-8	10
954	Einfluss der Überwachungskoloskopie auf das Mortalitätsrisiko von Patienten mit chronisch-entzündlichen Darmerkrankungen. 2010 , 5, 264-265	
953	Dysplasie colique et cancer colorectal: épidémiologie. 2010 , 4, 206-211	
952	Predictors of endoscopic colorectal cancer screening over time in 11 states. 2010 , 21, 445-61	226
951	Mesalamine protects against colorectal cancer in inflammatory bowel disease. 2010 , 55, 1696-703	52
950	The impact of ulcerative colitis on patients' lives compared to other chronic diseases: a patient survey. 2010 , 55, 1044-52	47
949	Genes regulated by Nkx2-3 in sporadic and inflammatory bowel disease-associated colorectal cancer cell lines. 2010 , 55, 3171-80	20

948	Oxidative stress, inflammation, and cancer: how are they linked?. 2010 , 49, 1603-16	3065
947	Importance of mucosal healing in ulcerative colitis. 2010 , 16, 338-46	161
946	Widespread but not localized neoplasia in inflammatory bowel disease worsens the prognosis of colorectal cancer. 2010 , 16, 474-81	20
945	Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. 2010 , 16, 1352-6	74
944	Increased expression and cellular localization of spermine oxidase in ulcerative colitis and relationship to disease activity. 2010 , 16, 1557-66	35
943	CCL2 (pM levels) as a therapeutic agent in Inflammatory Bowel Disease models in mice. 2010 , 16, 1496-504	13
942	Single nucleotide polymorphisms of 8 inflammation-related genes and their associations with smoking-related cancers. 2010 , 127, 2169-82	35
941	Polymorphisms in inflammatory pathway genes and their association with colorectal cancer risk. 2010 , 127, 2822-30	15
940	Ulcerative colitis and cancer. 2010 , 101, 706-12	58
939	Single nucleotide polymorphisms in the hypoxia-inducible factor-1 gene and colorectal cancer risk. 2010 , 49, 805-9	29
938	Aberrant methylation of DAPK in long-standing ulcerative colitis and ulcerative colitis-associated carcinoma. 2010 , 206, 616-24	27
937	Similarity in the metabolic profile in macroscopically involved and un-involved colonic mucosa in patients with inflammatory bowel disease: an in vitro proton ((1)H) MR spectroscopy study. 2010 , 28, 1022-9	32
936	Endoscopic surveillance in colitis in 2010: time for a change?. 2010 , 80, 125-6	
935	Near-infrared fluorescence imaging using a protease-specific probe for the detection of colon tumors. 2010 , 4, 488-97	20
934	Ligand-induced tyrosine phosphorylation of cysteinyl leukotriene receptor 1 triggers internalization and signaling in intestinal epithelial cells. 2010 , 5, e14439	24
933	Clinical Features in Patients with Ulcerative Colitis. 2010 , 46, 177	
932	Oral budesonide for induction of remission in ulcerative colitis. 2010 , CD007698	30
931	Increased expression of DNA methyltransferase-1 in non-neoplastic epithelium helps predict colorectal neoplasia risk in ulcerative colitis. 2010 , 82, 179-86	20

930	IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. 2010 , 185, 4912-20	262
929	Probiotics in Cancer Prevention. 2010 , 497-511	1
928	A practical guide and review of colonoscopic surveillance and chromoendoscopy in patients with colitis. 2010 , 1, 126-130	5
927	Lifestyle factors and p53 mutation patterns in colorectal cancer patients in the EPIC-Norfolk study. 2010 , 25, 351-8	12
926	Low incidence of colorectal dysplasia and cancer among patients with ulcerative colitis: a Turkish referral centre study. 2010 , 45, 434-9	16
925	S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). 2010 , 48, 65-136	73
924	Inflammatory bowel disease as a risk factor for colorectal cancer. 2010 , 28, 619-24	67
923	Induction of epigenetic alterations by chronic inflammation and its significance on carcinogenesis. 2010 , 71, 41-56	39
922	Array-based comparative genomic hybridization in ulcerative colitis neoplasia: single non-dysplastic biopsies distinguish progressors from non-progressors. 2010 , 23, 1624-33	9
921	DNA methylation of ESR-1 and N-33 in colorectal mucosa of patients with ulcerative colitis (UC). 2010 , 5, 422-6	21
920	Pathology analysis reveals that dysplastic pancreatic ductal lesions are frequent in patients with hereditary pancreatitis. 2010 , 8, 206-12	38
919	Colorectal carcinoma and preceding fistula in Crohn's disease. 2010 , 4, 189-93	11
918	Altered mRNA expression of telomere binding proteins (TPP1, POT1, RAP1, TRF1 and TRF2) in ulcerative colitis and Crohn's disease. 2010 , 42, 544-8	13
917	Novel methylation panel for the early detection of colorectal tumors in stool DNA. 2010 , 9, 168-76	52
916	Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. 2010 , 138, 595-605, 605.e1-3	53
915	AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. 2010 , 138, 746-74, 774.e1-4; quiz e12-3	354
914	Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. 2010 , 138, 1697-703	104
913	Risk factors for neoplasia in inflammatory bowel disease patients with pancolitis. 2010 , 105, 2405-11	57

912	Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. 2010 , 31, 37-49	468
911	Genetic dissection of intermediate phenotypes as a way to discover novel cancer susceptibility alleles. 2010 , 20, 308-14	5
910	Low expression of CysLT1R and high expression of CysLT2R mediate good prognosis in colorectal cancer. 2010 , 46, 826-35	56
909	Early lesions induced in rat colon epithelium by N-methyl-N'-nitro-N-nitrosoguanidine. 2010 , 42, 190-4	4
908	Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). 2010 , 59, 666-89	843
907	Cancer Genome and Tumor Microenvironment. 2010 ,	2
906	Investigating neoplastic progression of ulcerative colitis with label-free comparative proteomics. 2011 , 10, 200-9	32
905	Backwash ileitis does not affect pouch outcome in patients with ulcerative colitis with restorative proctocolectomy. 2011 , 9, 981-8	23
904	Dysplasia surveillance in an ulcerative colitis patient: successful detection with narrow band imaging and magnification. 2011 , 5, 54-6	2
903	Cancer in inflammatory bowel disease 15 years after diagnosis in a population-based European Collaborative follow-up study. 2011 , 5, 430-42	36
902	Progression of low-grade dysplasia in ulcerative colitis: effect of colonic location. 2011 , 74, 1087-93	47
901	Molecular pathways underlying IBD-associated colorectal neoplasia: therapeutic implications. 2011 , 106, 719-30	34
900	Microbial induction of immunity, inflammation, and cancer. 2011 , 1, 168	81
899	New Findings in the Diagnosis and Prevention of Colorectal Cancer in IBD. 2011 , 265-280	
898	Post FMC-HGE. 2011 ,	
897	Berries and Cancer Prevention. 2011 ,	2
896	Gastrointestinal Oncology. 2011 ,	
895	Clinical features, treatment, and survival of patients with colorectal cancer with or without inflammatory bowel disease. 2011 , 9, 584-9.e1-2	30

894	Chemoprevention of colorectal cancer in inflammatory bowel disease. 2011 , 25, 593-606	28
893	N-nitroso compound exposure-associated transcriptomic profiles are indicative of an increased risk for colorectal cancer. 2011 , 309, 1-10	28
892	Guidelines for the management of inflammatory bowel disease in adults. 2011 , 60, 571-607	927
891	The role of inflammation in the pathogenesis of lung cancer. 2011 , 15, 1127-37	87
890	Gastrointestinal cancer: current screening strategies. 2011 , 185, 149-57	3
889	Neoplasia in IBD. 2011 ,	
888	Molecular Determinants in Ulcerative Colitis [Epigenetics and Telomere Dysfunction. 2011 ,	
887	Endoscopic Approach in Ulcerative Colitis. 2011 ,	
886	Colonoscopy in surveillance of inflammatory bowel disease. 2011 , 9, 20-28	
885	[The role of NF-kappaB in colon cancer]. 2011 , 57, 3-7	6
884	Chronic Inflammation and Malignancy in Ulcerative Colitis. 2011 , 2011, 1-8	12
883	Mucosal healing in ulcerative colitis: where do we stand?. 2011 , 12, 1417-23	15
882	How to manage the risk of colorectal cancer in ulcerative colitis. 2011 , 12, 1424-32	4
881	Aberrant methylation of PSD disturbs Rac1-mediated immune responses governing neutrophil chemotaxis and apoptosis in ulcerative colitis-associated carcinogenesis. 2012 , 40, 942-50	5
880	Aberrant methylation of the Pleckstrin and Sec7 domain-containing gene is implicated in ulcerative colitis-associated carcinogenesis through its inhibitory effect on apoptosis. 2012 , 40, 686-94	3
879	Colorectal carcinoma in inflammatory bowel disease: a comparison between Crohn's and ulcerative colitis. 2011 , 13, 1230-5	42
878	Low prevalence of colonoscopic surveillance of inflammatory bowel disease patients with longstanding extensive colitis: a clinical practice survey nested in the CESAME cohort. 2011 , 34, 188-95	40
877	Diverticular disease and the risk of colon cancer - a population-based case-control study. 2011 , 34, 675-81	57

876	Ulcerative colitis. 2011 , 39, 224-228	2
875	Regulation of inflammation in cancer by eicosanoids. 2011 , 96, 27-36	217
874	Alterations of microRNAs contribute to colon carcinogenesis. 2011 , 38, 734-42	69
873	The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. 2011 , 20, 649-60	282
872	Colon Cancer. 2011 , 325-377	
871	Colorectal Cancer: Epidemiology, Etiology, and Molecular Basis. 2011 , 669-690	1
870	Ulcerative Colitis in Children and Adolescents. 2011 , 490-504.e6	
869	The role of N-acetyltransferase 2 polymorphism in the etiopathogenesis of inflammatory bowel disease. 2011 , 56, 2073-80	6
868	Is inflammatory bowel disease an important risk factor among older persons with colorectal cancer in the United States? A population-based case-control study. 2011 , 56, 2378-83	21
867	Surveillance programmes for neoplasia in colitis. 2011 , 46 Suppl 1, 1-5	58
866	Association between polymorphisms in the XRCC1 and GST genes, and CpG island methylation status in colonic mucosa in ulcerative colitis. 2011 , 458, 205-11	8
865	Inflammatory bowel disease-associated colorectal cancer: proctocolectomy and mucosectomy do not necessarily eliminate pouch-related cancer incidences. 2011 , 26, 533-52	33
864	Aspects épidémiologiques des maladies inflammatoires chroniques de l'intestin dans une population algérienne. 2011 , 5, 293-302	4
863	IBD-related carcinoma and lymphoma. 2011 , 25 Suppl 1, S27-38	3
862	Cancer surveillance in patients with primary sclerosing cholangitis. 2011 , 54, 1842-52	204
861	Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use. 2011 , 117, 1640-8	38
860	Diagnosis and management of dysplasia and cancer of the ileal pouch in patients with underlying inflammatory bowel disease. 2011 , 117, 3081-92	45
859	Expression profiling of Wnt family of genes in normal and inflammatory bowel disease primary human intestinal myofibroblasts and normal human colonic crypt epithelial cells. 2011 , 17, 213-20	43

858	Oncogenic Smad3 signaling induced by chronic inflammation is an early event in ulcerative colitis-associated carcinogenesis. 2011 , 17, 683-95	28
857	Cancer surveillance strategies in ulcerative colitis: the need for modernization. 2011 , 17, 1800-13	20
856	Using optical markers of nondysplastic rectal epithelial cells to identify patients with ulcerative colitis-associated neoplasia. 2011 , 17, 2427-35	10
855	Rectal neuroendocrine tumor in ulcerative colitis. 2011 , 17, E106-7	5
854	Lung cancer in chronic obstructive pulmonary disease: enhancing surgical options and outcomes. 2011 , 183, 1138-46	80
853	Mutational hotspots in the mitochondrial D-loop region of cancerous and precancerous colorectal lesions in Egyptian patients. 2011 , 30, 899-906	15
852	Inflammatory Bowel Disease. 2011 ,	2
851	Cancer stem cells in ulcerative colitis. 2011 , 34, 660-2	
850	Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly. 2011 , 174, 860-70	102
849	Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer. 2011 , 108, 17420-5	47
848	Metabolic syndrome frequency in inflammatory bowel diseases. 2011 , 17, 376-82	23
847	Novel jumbo biopsy forceps for surveillance of inflammatory bowel disease: a comparative retrospective assessment. 2011 , 2011, 671659	2
846	Clinical and pathological implications of concurrent autoimmune thyroid disorders and papillary thyroid cancer. 2011 , 2011, 387062	27
845	Cytokine induction of tumor necrosis factor receptor 2 is mediated by STAT3 in colon cancer cells. 2011 , 9, 1718-31	44
844	Inflammatory bowel disease and colon cancer. 2011 , 185, 99-115	52
843	The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. 2011 , 106, 319-28	114
842	Epidemiology and Risk Factors of Colorectal Cancer. 2011 , 1-11	2
841	Is surveillance endoscopy necessary after colectomy in ulcerative colitis?. 2011 , 2011, 509251	9

840	Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study. 2012 , 47, 1021-9	41
839	Peritoneal sarcomatosis associated with telemetry implants in Sprague Dawley CD rats: a review of eight cases. 2012 , 40, 113-21	12
838	The dual role of inflammation in colon carcinogenesis. 2012 , 13, 11071-84	67
837	Modeling colitis-associated cancer with azoxymethane (AOM) and dextran sulfate sodium (DSS). 2012 ,	83
836	Incidence, treatment options, and outcomes of lung cancer in patients with chronic obstructive pulmonary disease. 2012 , 18, 131-7	26
835	Cancer in inflammatory bowel disease: lessons from animal models. 2012 , 28, 327-33	31
834	The influence of 5-aminosalicylic acid on the progression of colorectal adenomas via the E-catenin signaling pathway. 2012 , 33, 637-43	30
833	Is diverticular disease associated with colonic malignancy?. 2012 , 30, 46-50	8
832	Dietary folate suppresses DMH-induced colon carcinogenesis in a rat model and affects DMH-induced expression of four DNA repair enzymes. 2012 , 64, 1196-203	1
831	Ulcerative Colitis. 2012 , 1217-1229	
830	A hexane fraction of American ginseng suppresses mouse colitis and associated colon cancer: anti-inflammatory and proapoptotic mechanisms. 2012 , 5, 685-96	26
829	Lynch or not Lynch? Is that always a question?. 2012 , 113, 121-66	24
828	Six cases of primary colorectal cancer after living-donor liver transplantation: a single-institution experience in Japan. 2012 , 42, 586-90	3
827	Colorectal cancer chemoprevention by mesalazine and its derivatives. 2012 , 2012, 980458	21
826	Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling. 2012 , 40, 1533-42	23
825	Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. 2012 , 55, 93-108	80
824	Array-based identification of common DNA methylation alterations in ulcerative colitis. 2012 , 40, 983-94	17
823	Distinct clinicohistologic features of inflammatory bowel disease-associated colorectal adenocarcinoma: in comparison with sporadic microsatellite-stable and Lynch syndrome-related colorectal adenocarcinoma. 2012 , 36, 1228-33	65

822	Histomorphologic and molecular features of pouch and peripouch adenocarcinoma: a comparison with ulcerative colitis-associated adenocarcinoma. 2012 , 36, 1385-94	43
821	Surgery for ulcerative colitis: Outcomes in low volume hospitals versus high volume hospitals. 2012 ,	
820	Patología inflamatoria de recto y ano. 2012 , 11, 413-419	
819	Keratins in colorectal epithelial function and disease. 2012 , 93, 305-18	33
818	Ulcerative colitis. 2012 , 380, 1606-19	1036
817	Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. 2012 , 13, R79	1668
816	Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long-term survey. 2012 , 47, 1308-22	77
815	Prevalence and clinical relevance of Th17 cells in patients with gastric cancer. 2012 , 178, 685-91	52
814	Ileal Pouch-Anal Anastomosis: A Surgical Perspective. 2012 , 23, 110-116	
813	Surveillance Colonoscopy in Ulcerative Colitis: A Surgical Perspective. 2012 , 23, 75-80	
812	Decreased Toll-interacting protein and peroxisome proliferator-activated receptor γ are associated with increased expression of Toll-like receptors in colon carcinogenesis. 2012 , 65, 302-8	33
811	Role of mast cells in colorectal cancer development, the jury is still out. 2012 , 1822, 9-13	24
810	Colorectal Cancer. 2012 , 86-136	
809	Colitis and colorectal cancer. 2012 , 30, 469-76	25
808	Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. 2012 , 143, 375-81.e1; quiz e13-4	376
807	Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. 2012 , 143, 382-9	230
806	The effect of smoking on intestinal inflammation: what can be learned from animal models?. 2012 , 6, 1-12	33
805	Disease severity does not affect the interval between IBD diagnosis and the development of CRC: results from two large, Dutch case series. 2012 , 6, 435-40	9

804	Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. 2012 , 6, 476-82	20
803	Colorectal cancer screening and surveillance in Crohn's colitis. 2012 , 6, 824-9	22
802	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. 2012 , 6, 965-90	592
801	Rectocolite h�morragique : �pid�miologie, physiopathologie, diagnostic, histoire naturelle et strat�gie th�rapeutique. 2012 , 7, 1-19	1
800	Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. 2012 , 10, 639-45	549
799	A novel murine model of inflammatory bowel disease and inflammation-associated colon cancer with ulcerative colitis-like features. 2012 , 7, e41797	33
798	Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(�) mesalamine. 2012 , 4, 41-50	10
797	Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?. 2012 , 18, 3839-48	154
796	Colorectal Cancer in Ulcerative Colitis Patients. 2012 ,	
795	Ulcerative Colitis-Associated Colorectal Cancer Prevention by 5-Aminosalicylates: Current Status and Perspectives. 2012 ,	
794	Epstein-Barr virus-negative aggressive natural killer-cell leukaemia with high P-glycoprotein activity and phosphorylated extracellular signal-regulated protein kinases 1 and 2. 2012 , 4, e16	6
793	Clinical and biological implications of the tumor microenvironment. 2012 , 5, 95-112	54
792	Risk of colorectal cancer among Caucasian and African American veterans with ulcerative colitis. 2012 , 18, 1011-7	18
791	Colorectal cancer in inflammatory bowel diseases: a population-based study (1976-2008). 2012 , 18, 2247-51	40
790	Potential usefulness of DNA methylation as a risk marker for digestive cancer associated with inflammation. 2012 , 12, 489-97	8
789	Survival in elderly patients with ulcerative colitis and colorectal cancer. 2012 , 57, 1435-8	2
788	Managing risks of neoplasia in inflammatory bowel disease. 2012 , 14, 174-80	5
787	Ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing cholangitis for prevention of colon cancer: a meta-analysis. 2012 , 31, 69-74	13

786	Kolorektales Karzinom bei chronisch entzündlichen Darmerkrankungen. 2012 , 18, 248-253	1
785	Malignancies and mortality in 200 patients with primary sclerosing cholangitis: a long-term single-centre study. 2012 , 32, 214-22	67
784	Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction. 2012 , 167, 188-94	21
783	Inflammatory bowel disease. 2012 , 18, 1-15	35
782	Current controversies in the management of colon cancer. 2012 , 49, 398-460	8
781	Myeloperoxidase immunohistochemistry as a measure of disease activity in ulcerative colitis: association with ulcerative colitis-colorectal cancer, tumor necrosis factor polymorphism and RUNX3 methylation. 2012 , 18, 275-83	39
780	Outcome of sporadic adenomas and adenoma-like dysplasia in patients with ulcerative colitis undergoing polypectomy. 2012 , 18, 226-35	54
779	MicroRNAs in inflammatory bowel disease. 2012 , 18, 187-93	109
778	Risk of ulcerative colitis-associated colorectal cancer in China: a multi-center retrospective study. 2012 , 57, 503-7	40
777	Novel methylation panel for the early detection of neoplasia in high-risk ulcerative colitis and Crohn's colitis patients. 2013 , 19, 165-73	30
776	Decreased systemic IGF-1 in response to calorie restriction modulates murine tumor cell growth, nuclear factor- κ B activation, and inflammation-related gene expression. 2013 , 52, 997-1006	44
775	The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis. 2013 , 20, 1485-97	50
774	Backwash ileitis and the risk of colon neoplasia in ulcerative colitis patients undergoing restorative proctocolectomy. 2013 , 58, 2019-27	8
773	The cysteinyl leukotriene 2 receptor contributes to all-trans retinoic acid-induced differentiation of colon cancer cells. 2013 , 13, 336	19
772	IL-22 is related to development of human colon cancer by activation of STAT3. 2013 , 13, 59	128
771	Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/βcatenin signaling via its FadA adhesin. 2013 , 14, 195-206	1082
770	Riboflavin depletion of intestinal cells in vitro leads to impaired energy generation and enhanced oxidative stress. 2013 , 52, 1513-21	9
769	Immunohistochemical analysis of the DNA methyltransferase 3b expression is associated with significant improvements in the discrimination of ulcerative colitis-associated neoplastic lesions. 2013 , 43, 1275-80	3

768	History of and current issues affecting surgery for pediatric ulcerative colitis. 2013 , 43, 1219-31	11
767	Detección precoz del cáncer colorrectal. 2013 , 17, 1-8	
766	Inflammatory bowel disease and familial adenomatous polyposis. 2013 , 7, e103-7	9
765	Evolving endoscopic strategies for detection and treatment of neoplastic lesions in inflammatory bowel disease. 2013 , 77, 351-9	22
764	The Association Between Inflammation and Colorectal Cancer. 2013 , 67-105	1
763	CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. 2013 , 24, 631-44	306
762	European evidence based consensus for endoscopy in inflammatory bowel disease. 2013 , 7, 982-1018	560
761	Cutaneous manifestations of gastrointestinal disease: part II. 2013 , 68, 211.e1-33; quiz 244-6	84
760	Clinicopathological features of ulcerative colitis-associated colorectal cancer pointing to efficiency of surveillance colonoscopy in a large retrospective Japanese cohort. 2013 , 28, 829-34	18
759	Ulcerative colitis: comparison between elderly and young adult patients and between elderly patients with late-onset and long-standing disease. 2013 , 58, 1306-12	16
758	Crosstalk between colon cancer cells and macrophages via inflammatory mediators and CD47 promotes tumour cell migration. 2013 , 49, 3320-34	95
757	Systems Biology of Tumor Dormancy. 2013 ,	6
756	Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs. 2013 , 734, 91-107	26
755	The burden of inflammatory bowel disease in Europe. 2013 , 7, 322-37	583
754	Meta-analyses of colorectal cancer risk factors. 2013 , 24, 1207-22	394
753	Infectious and malignant complications of TNF inhibitor therapy in IBD. 2013 , 108, 1835-42, quiz 1843	79
752	Rate of early/missed colorectal cancers after colonoscopy in older patients with or without inflammatory bowel disease in the United States. 2013 , 108, 444-9	62
751	NSAIDs and selectively COX-2 inhibitors as potential chemoprotective agents against cancer: 1st Cancer Update. 2013 , 6, 1-23	20

750	Overexpression of microRNAs-155 and 21 targeting mismatch repair proteins in inflammatory bowel diseases. 2013 , 34, 828-34	45
749	Looking forward to understanding and reducing colorectal cancer risk in inflammatory bowel disease. 2013 , 145, 47-49	1
748	Endoscopic Findings in Ulcerative Colitis. 2013 , 1, 330-331	
747	E. coli and colon cancer: is mutY a culprit?. 2013 , 341, 127-31	10
746	Molecular diagnostic algorithms in hepatocellular carcinoma: dead-end street or light at the end of the tunnel?. 2013 , 145, 49-53	5
745	Bibliometrics of the top 100 clinical articles in digestive disease. 2013 , 144, 673-676.e5	22
744	Plasminogen activator inhibitor-1 is increased in colonic epithelial cells from patients with colitis-associated cancer. 2013 , 7, 403-11	5
743	Role of arachidonic acid metabolites on the control of non-differentiated intestinal epithelial cell growth. 2013 , 45, 1620-8	40
742	Tumour necrosis factor and cancer. 2013 , 230, 241-8	136
741	Lifestyle modification in colorectal cancer patients: an integrative oncology approach. 2013 , 9, 207-18	17
740	Mechanisms of Gastrointestinal Carcinogenesis. 2013 , 3-29	
739	Dysplastic lesions in inflammatory bowel disease: molecular pathogenesis to morphology. 2013 , 137, 338-50	50
738	Application of liposomes in drug development--focus on gastroenterological targets. 2013 , 8, 1325-34	20
737	Chronisch-entzündliche Erkrankungen des Kolorektums. 2013 , 571-609	
736	Surveillance endoscopique de la dysplasie dans les maladies inflammatoires chroniques de l'intestin. 2013 , 43, 207-213	3
735	Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. 2013 , 145, 166-175.e8	228
734	Calcitonin gene-related peptide is a promising marker in ulcerative colitis. 2013 , 58, 686-93	10
733	Rage signalling promotes intestinal tumourigenesis. 2013 , 32, 1202-6	46

732	[Colorectal cancer: screening and surveillance in inflammatory bowel diseases - consensus of the working group for inflammatory bowel diseases of the Austrian Society of Gastroenterology and Hepatology]. 2013 , 51, 450-7	1
731	Gut microbiota protects against gastrointestinal tumorigenesis caused by epithelial injury. 2013 , 73, 7199-210	73
730	Tumor suppressor function of the plasma glutathione peroxidase gpx3 in colitis-associated carcinoma. 2013 , 73, 1245-55	116
729	Fate of the rectal stump after subtotal colectomy for ulcerative colitis in the era of ileal pouch-anal anastomosis. 2013 , 148, 408-11	31
728	Infiltration of tumor-associated macrophages is increased in the epithelial and stromal compartments of endometrial carcinomas. 2013 , 32, 576-84	21
727	DNA methylation biomarkers for noninvasive diagnosis of colorectal cancer. 2013 , 6, 656-65	95
726	Risk of cancer in patients with autoimmune pancreatitis. 2013 , 108, 610-7	161
725	Dipeptidase 1 (DPEP1) is a marker for the transition from low-grade to high-grade intraepithelial neoplasia and an adverse prognostic factor in colorectal cancer. 2013 , 109, 694-703	25
724	Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer. 2013 , 110, 13091-6	94
723	Virtual chromoendoscopy for prediction of severity and disease extent in patients with inflammatory bowel disease: a randomized controlled study. 2013 , 19, 1935-42	39
722	Gene signature distinguishes patients with chronic ulcerative colitis harboring remote neoplastic lesions. 2013 , 19, 461-70	30
721	Dietary folate does not significantly affect the intestinal microbiome, inflammation or tumorigenesis in azoxymethane-dextran sodium sulphate-treated mice. 2013 , 109, 630-8	17
720	MicroRNA-224 negatively regulates p21 expression during late neoplastic progression in inflammatory bowel disease. 2013 , 19, 471-80	48
719	Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. 2013 , 19, 789-99	266
718	Strategies for detecting colon cancer and dysplasia in patients with inflammatory bowel disease. 2013 , 19, 860-3	23
717	Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells. 2013 , 19, 2051-60	16
716	Overview of molecular pathways in inflammatory bowel disease associated with colorectal cancer development. 2013 , 25, 271-81	61
715	Chromoendoscopy versus narrow band imaging for colonic surveillance in inflammatory bowel disease. 2013 , 19, 2132-8	59

714	DNA hypermethylation of a selective gene panel as a risk marker for colon cancer in patients with ulcerative colitis. 2013 , 31, 1255-61	26
713	A thirty-year follow-up surveillance study for neoplasia of a dutch ulcerative colitis cohort. 2013 , 2013, 274715	7
712	Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab. 2013 , 7, 289-96	8
711	Dietary selenium deficiency exacerbates DSS-induced epithelial injury and AOM/DSS-induced tumorigenesis. 2013 , 8, e67845	64
710	CysLT(1)R antagonists inhibit tumor growth in a xenograft model of colon cancer. 2013 , 8, e73466	42
709	Dietary iron enhances colonic inflammation and IL-6/IL-11-Stat3 signaling promoting colonic tumor development in mice. 2013 , 8, e78850	46
708	NF- κ B and cancer. 336-352	
707	Synchronous colorectal neoplasms in ulcerative pancolitis of 6 years duration: pathological and molecular heterogeneity. 2013 , 2013,	1
706	Myosin light chain kinase expression induced via tumor necrosis factor receptor 2 signaling in the epithelial cells regulates the development of colitis-associated carcinogenesis. 2014 , 9, e88369	32
705	Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. 2014 , 20, 9872-81	230
704	Ulcerative colitis: from inflammation to cancer. Do estrogen receptors have a role?. 2014 , 20, 11496-504	26
703	Inflammatory Bowel Disease-related Colorectal Cancer in the Asia-Pacific Region: Past, Present, and Future. 2014 , 12, 194-204	40
702	Ulcerative colitis-associated colorectal cancer. 2014 , 20, 16389-97	110
701	Defining quality indicators for best-practice management of inflammatory bowel disease in Canada. 2014 , 28, 275-85	39
700	The Risk of Colon Cancer in Inflammatory Bowel Disease. 2014 , 04,	
699	Clinical review of pulmonary manifestations of IgG4-related disease. 2014 , 11, 1466-75	54
698	Inflammatory bowel disease and neoplasia in children. 2014 , 32, 455-62	2
697	Colorectal cancer in inflammatory bowel disease: a shift in risk?. 2014 , 14, 847-56	5

696	[Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis (Spanish version)]. 2014 , 79, 263-89	11
695	Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. 2014 , 39, 645-59	169
694	COPD-related adenocarcinoma presents low aggressiveness morphological and molecular features compared to smoker tumours. 2014 , 86, 311-7	11
693	Kimchi protects against azoxymethane/dextran sulfate sodium-induced colorectal carcinogenesis in mice. 2014 , 17, 833-41	22
692	A matched case-control study of IBD-associated colorectal cancer: IBD portends worse outcome. 2014 , 109, 117-21	20
691	Nrf2-Target Approaches in Cancer Chemoprevention Mediated by Dietary Phytochemicals. 2014 , 53-83	2
690	C-reactive protein and risk of colorectal adenomas or serrated polyps: a prospective study. 2014 , 7, 1122-7	9
689	Myeloid-derived suppressor cells link inflammation to cancer. 2014 , 3, e28581	7
688	Implications of the colonic deposition of free hemoglobin- β -chain: a previously unknown tissue by-product in inflammatory bowel disease. 2014 , 20, 1530-47	13
687	Dysplasia in ulcerative colitis as a predictor of unsuspected synchronous colorectal cancer. 2014 , 57, 993-8	19
686	Practice parameters for the surgical treatment of ulcerative colitis. 2014 , 57, 5-22	118
685	Interactions between <i>Trichinella spiralis</i> infection and induced colitis in mice. 2014 , 88, 210-8	13
684	Pathology of Pediatric Gastrointestinal and Liver Disease. 2014 ,	5
683	Oestrogens promote tumorigenesis in a mouse model for colitis-associated cancer. 2014 , 63, 310-6	31
682	Immune response in thyroid cancer: widening the boundaries. 2014 , 2014, 125450	19
681	Use of surveillance colonoscopy in medicare patients with inflammatory bowel disease prior to colorectal cancer diagnosis. 2014 , 90, 58-62	7
680	Advanced endoscopic imaging for surveillance for dysplasia and colorectal cancer in inflammatory bowel disease: could the pathologist be further helped?. 2014 , 20, 26-38	6
679	37-year-old man with abdominal pain. 2014 , 89, 558-62	

678	Monochloramine suppresses the proliferation of colorectal cancer cell line Caco-2 by both apoptosis and G2/M cell cycle arrest. 2014 , 32, 188-93	3
677	Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis. 2014 , 35, 6195-206	78
676	Animal models of gastrointestinal inflammation and cancer. 2014 , 108, 1-6	10
675	The inflammatory mediator leukotriene D ₄ induces subcellular E-catenin translocation and migration of colon cancer cells. 2014 , 321, 255-66	38
674	Inflammatory bowel disease cancer surveillance in a tertiary referral hospital: attitudes and practice. 2014 , 44, 40-9	9
673	Current overview of colitis-associated colorectal cancer. 2014 , 9, 1022-1029	4
672	Peroxisome proliferator-activated receptor γ promotes colonic inflammation and tumor growth. 2014 , 111, 7084-9	60
671	Immune chaperone gp96 drives the contributions of macrophages to inflammatory colon tumorigenesis. 2014 , 74, 446-59	52
670	Association between allergic rhinitis and nasopharyngeal carcinoma: a population-based study. 2014 , 124, 1744-9	15
669	Importance of nonpolypoid (flat and depressed) colorectal neoplasms in screening for CRC in patients with IBD. 2014 , 24, 327-35	12
668	Interval colorectal cancers in inflammatory bowel disease: the grim statistics and true stories. 2014 , 24, 337-48	20
667	Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature. 2014 , 8, 1351-61	86
666	Colitis-associated neoplasia: molecular basis and clinical translation. 2014 , 71, 3523-35	36
665	Inter-observer and intra-observer variability in the diagnosis of dysplasia in patients with inflammatory bowel disease: correlation of pathological and endoscopic findings. 2014 , 16, 710-8; discussion 718	24
664	Cancer risk after resection of polypoid dysplasia in patients with longstanding ulcerative colitis: a meta-analysis. 2014 , 12, 756-64	130
663	Association of rhinosinusitis with nasopharyngeal carcinoma: a population-based study. 2014 , 124, 1515-20	20
662	An analysis of genetic factors related to risk of inflammatory bowel disease and colon cancer. 2014 , 38, 583-90	22
661	Chromoendoscopy for colorectal cancer surveillance in patients with inflammatory bowel disease. 2014 , 16, 407	8

660	Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I). 2014 , 8, 5-18	89
659	Surgical management of nonpolypoid colorectal lesions and strictures in colonic inflammatory bowel disease. 2014 , 24, 447-54	19
658	Toward a consensus on endoscopic surveillance of patients with colonic inflammatory bowel disease. 2014 , 24, 469-81	15
657	Avoiding rash decision making: skin cancer screening of patients with inflammatory bowel disease. 2014 , 12, 274-6	1
656	Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. 2014 , 12, 265-73.e1	142
655	DNA methylation of microRNA-124a is a potential risk marker of colitis-associated cancer in patients with ulcerative colitis. 2014 , 59, 2444-51	37
654	Epidemiology. 2014 , 1-26	1
653	Tumours of the small and large bowel. 2014 , 308-320	
652	Colorectal Cancer in Inflammatory Bowel Disease: Epidemiology, Pathogenesis and Surveillance. 2014 , 1, 146-54	19
651	Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. 2014 , 20, 398-415	25
650	Lobar lung resection in elderly patients with non-small cell lung carcinoma: impact of chronic obstructive pulmonary disease on surgical outcome. 2014 , 99, 319-24	3
649	Clinical-pathological and p53 protein expression study in dysplasia associated with ulcerative colitis. 2014 , 34, 136-140	
648	FGF-1/-3/FGFR4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7. 2015 , 106, 1278-87	59
647	Death-associated protein kinase: A molecule with functional antagonistic duality and a potential role in inflammatory bowel disease (Review). 2015 , 47, 5-15	13
646	The impact of inflammatory lipid mediators on colon cancer-initiating cells. 2015 , 54, 1315-27	15
645	Inflammation decreases keratin level in ulcerative colitis; inadequate restoration associates with increased risk of colitis-associated cancer. 2015 , 2, e000024	12
644	Aberrant Niche Signaling in the Etiopathogenesis of Ulcerative Colitis. 2015 , 21, 2549-61	6
643	Oral budesonide for induction of remission in ulcerative colitis. 2015 , CD007698	34

642	Colorectal cancer in colitis: a relic of the past?. 2015 , 21, 699-702	2
641	Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis. 2015 , 21, 2562-9	24
640	Elevated expression of interleukin-21 and its correlation to T-cell subpopulation in patients with ulcerative colitis. 2015 , 40, 331-6	4
639	Colitis-associated colon cancer: Is it in your genes?. 2015 , 21, 11688-99	29
638	Smad2/3 linker phosphorylation is a possible marker of cancer stem cells and correlates with carcinogenesis in a mouse model of colitis-associated colorectal cancer. 2015 , 9, 565-74	14
637	MicroRNA214 Is Associated With Progression of Ulcerative Colitis, and Inhibition Reduces Development of Colitis and Colitis-Associated Cancer in Mice. 2015 , 149, 981-92.e11	90
636	Colorectal neoplasia in IBD--a single-center analysis of patients undergoing proctocolectomy. 2015 , 30, 821-9	3
635	Extent of disease is a major outcome predictor in patients with ulcerative colitis and pregnancy. 2015 , 34, 108-11	5
634	New endoscopic imaging techniques in surveillance of inflammatory bowel disease. 2015 , 7, 230-6	11
633	Serbest radikaller, sİ serumu proteinleri ve kolorektal kanser. 2015 , 27, 1	0
632	Geranylgeranylacetone suppresses colitis-related mouse colon carcinogenesis. 2015 , 33, 1769-74	4
631	Never in mitosis gene A-related kinase 6 and aurora kinase A: New gene biomarkers in the conversion from ulcerative colitis to colorectal cancer. 2015 , 34, 1905-14	15
630	Qing Hua Chang Yin inhibits the LPS-induced activation of the IL-6/STAT3 signaling pathway in human intestinal Caco-2 cells. 2015 , 35, 1133-7	7
629	Who and how to screen for cancer in at-risk inflammatory bowel disease patients. 2015 , 9, 731-46	8
628	Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. 2015 , 112, 1088-97	99
627	Malignancies in inflammatory bowel disease. 2015 , 50, 81-9	10
626	Fusobacterium detected in colonic biopsy and clinicopathological features of ulcerative colitis in Japan. 2015 , 60, 205-10	40
625	The risk of colorectal cancer in patients with ulcerative colitis. 2015 , 60, 492-501	30

624	The epidemiology of inflammatory bowel disease. 2015 , 50, 942-51	208
623	15-Lipoxygenase-1 suppression of colitis-associated colon cancer through inhibition of the IL-6/STAT3 signaling pathway. 2015 , 29, 2359-70	28
622	Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. 2015 , 148, 1035-1058.e3	251
621	Classification and diagnosis of colorectal dysplasia in inflammatory bowel disease. 2015 , 21, 283-289	0
620	Inflammation and Lung Cancer: Molecular Pathology. 2015 , 69-93	
619	Paediatric ulcerative colitis surgery: Italian survey. 2015 , 9, 558-64	10
618	Low interobserver agreement among endoscopists in differentiating dysplastic from non-dysplastic lesions during inflammatory bowel disease colitis surveillance. 2015 , 50, 1011-7	10
617	Inflammation and Lung Cancer. 2015 ,	0
616	Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study). 2015 , 50, 1456-62	30
615	Chromocolonoscopy. 2015 , 25, 243-60	13
614	The immune microenvironment of the colorectal tumor: Involvement of immunity genes and microRNAs belonging to the TH17 pathway. 2015 , 1856, 28-38	16
613	The role of endoscopy in inflammatory bowel disease. 2015 , 81, 1101-21.e1-13	216
612	Macrophage migration inhibitory factor: a key cytokine and therapeutic target in colon cancer. 2015 , 26, 451-61	39
611	Surgical management of ulcerative colitis in the era of biologicals. 2015 , 21, 208-20	18
610	Chromoendoscopy for Surveillance in Inflammatory Bowel Disease Does Not Increase Neoplasia Detection Compared With Conventional Colonoscopy With Random Biopsies: Results From a Large Retrospective Study. 2015 , 110, 1014-21	83
609	Ulcerative colitis. 2015 , 43, 276-281	5
608	Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease. 2015 , 60, 2251-63	35
607	Cancers complicating inflammatory bowel disease. <i>New England Journal of Medicine</i> , 2015 , 372, 1441-52.59.2	337

606	Inflammatory bowel disease. 2015 , 50, 748-62	23
605	Thiopurine Therapy Reduces the Incidence of Colorectal Neoplasia in Patients with Ulcerative Colitis. Data from the ENEIDA Registry. 2015 , 9, 1063-70	36
604	Bioactives in Commonly Consumed Cereal Grains: Implications for Oxidative Stress and Inflammation. 2015 , 18, 1179-86	16
603	Colorectal Neoplasia and Inflammatory Bowel Disease. 2015 , 95, 1261-9, vii	15
602	Mucinous adenocarcinoma emerging in sigmoid colon neovagina 40 years after its creation: a case report. 2015 , 13, 213	14
601	Elevated fecal M2-pyruvate kinase in children with cystic fibrosis: a clue to the increased risk of intestinal malignancy in adulthood?. 2015 , 30, 866-71	22
600	Surveillance of long-standing colitis: the role of image-enhanced endoscopy. 2015 , 29, 687-97	1
599	Incidence of Interval Colorectal Cancer Among Inflammatory Bowel Disease Patients Undergoing Regular Colonoscopic Surveillance. 2015 , 13, 1656-61	52
598	Endoscopy in Inflammatory Bowel Disease. 2015 ,	
597	Signaling Pathways that Facilitate Chronic Inflammation-Induced Carcinogenesis. 2016 , 01,	
596	Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. 2016 , 22, 4794-801	219
595	Advanced gastrointestinal endoscopic imaging for inflammatory bowel diseases. 2016 , 22, 1246-59	10
594	Biomarkers for colitis-associated colorectal cancer. 2016 , 22, 7882-91	18
593	Chronic Inflammation in Skin Malignancies. 2016 , 11, 2	26
592	Elderly patients and inflammatory bowel disease. 2016 , 7, 51-65	36
591	Oxidative Stress and Carbonyl Lesions in Ulcerative Colitis and Associated Colorectal Cancer. 2016 , 2016, 9875298	79
590	Novel Synthetic Oxazines Target NF- κ B in Colon Cancer In Vitro and Inflammatory Bowel Disease In Vivo. 2016 , 11, e0163209	30
589	How to Optimize Colon Cancer Surveillance in Inflammatory Bowel Disease Patients. 2016 , 22, 1219-30	15

588	What is the likelihood of colorectal cancer when surgery for ulcerative-colitis-associated dysplasia is deferred?. 2016 , 18, 703-9	5
587	Autologous bone marrow stem cell transplantation for the treatment of ulcerative colitis complicated with herpes zoster: a case report. 2016 , 10, 522-526	3
586	Ulcerative Colitis-associated Cancer/Dysplasia Detected Using Surveillance Colonoscopy Performed in the Clinical Remission Phase: A Report of Five Cases. 2016 , 55, 911-7	1
585	Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer. 2016 , 16, 425-33	13
584	High tumor mast cell density is associated with longer survival of colon cancer patients. 2016 , 55, 1434-1442	26
583	The Significance of Sessile Serrated Polyps in Inflammatory Bowel Disease. 2016 , 22, 2213-20	21
582	Inflammatory cytokines and non-small cell lung cancer in a CT-scan screening cohort: Background review of the literature. 2016 , 16, 219-33	15
581	The 100 most influential manuscripts in colorectal cancer: A bibliometric analysis. 2016 , 14, 327-336	20
580	Regulatory T Cells and Cancer: A Two-Sided Story. 2016 , 45, 797-812	30
579	Endoscopic evaluation for colon cancer and dysplasia in patients with inflammatory bowel disease. 2016 , 18, 145-151	1
578	Large bowel cancer in the setting of inflammatory bowel disease. 2016 , 48, 191-202	3
577	The continuing uncertainty about cancer risk in inflammatory bowel disease. 2016 , 65, 889-93	41
576	Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management. 2016 , 9, 887-894	92
575	Patients with Endoscopically Visible Polypoid Adenomatous Lesions Within the Extent of Ulcerative Colitis Have an Increased Risk of Colorectal Cancer Despite Endoscopic Resection. 2016 , 61, 3031-3036	3
574	Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study. 2016 , 111, 1428-1436	44
573	Effect of appendicectomy on colonic inflammation and neoplasia in experimental ulcerative colitis. 2016 , 103, 1530-8	16
572	Surveillance colonoscopy for colitis-associated dysplasia and cancer in ulcerative colitis patients. 2016 , 28, 260-5	16
571	The 100 classic papers in ulcerative colitis: a bibliometric analysis. 2016 , 10, 1187-1195	7

570	Is Coenzyme Q10 Effective in Protection against Ulcerative Colitis? An Experimental Study in Rats. 2016 , 39, 1159-66	7
569	Nutrient-Gene Interaction in Colon Cancer, from the Membrane to Cellular Physiology. 2016 , 36, 543-70	27
568	The eicosanoids leukotriene D4 and prostaglandin E2 promote the tumorigenicity of colon cancer-initiating cells in a xenograft mouse model. 2016 , 16, 425	20
567	Geijigajakyak decoction inhibits the motility and tumorigenesis of colorectal cancer cells. 2016 , 16, 288	4
566	Higher Risk for Hematological Malignancies in Inflammatory Bowel Disease: A Nationwide Population-based Study in Taiwan. 2016 , 111, 1313-9	21
565	Epidemiology, risk factors, and prevention. 2016 , 27, 176-180	1
564	Gastrointestinal Physiology and Diseases. 2016 ,	0
563	AOM/DSS Model of Colitis-Associated Cancer. 2016 , 1422, 297-307	79
562	Collision adenocarcinoma/ carcinoid tumor of the rectum arising in ulcerative colitis. 2016 , 7, 39-42	
561	TNF-alpha promotes lymphangiogenesis and lymphatic metastasis of gallbladder cancer through the ERK1/2/AP-1/VEGF-D pathway. 2016 , 16, 240	33
560	Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. 2016 , 10, 1385-1394	74
559	Mapping hyper-susceptibility to colitis-associated colorectal cancer in FVB/NJ mice. 2016 , 27, 213-24	
558	Clinical pattern and progression of ulcerative proctitis in the Japanese population: a retrospective study of incidence and risk factors influencing progression. 2016 , 18, O97-O102	10
557	Associations between markers of colorectal cancer stem cells, mutation, microRNA and the clinical features of ulcerative colitis. 2016 , 18, O185-93	4
556	Epithelial Nuclear Factor- κ B Activation in Inflammatory Bowel Diseases and Colitis-Associated Carcinogenesis. 2016 , 93, 40-6	5
555	A roadmap to the implementation of chromoendoscopy in inflammatory bowel disease colonoscopy surveillance practice. 2016 , 83, 213-22	24
554	Colorectal Cancer Screening in Inflammatory Bowel Disease. 2016 , 61, 980-9	25
553	Chromoendoscopy Is More Effective Than Standard Colonoscopy in Detecting Dysplasia During Long-term Surveillance of Patients With Colitis. 2016 , 14, 713-9	45

552	Colorectal Cancer in Patients With Inflammatory Bowel Disease: The Need for a Real Surveillance Program. 2016 , 15, 204-12	28
551	Synthesis and Structure-Activity Relationships of N-Dihydrocoptisine-8-ylidene Aromatic Amines and N-Dihydrocoptisine-8-ylidene Aliphatic Amides as Antiulcerative Colitis Agents Targeting XBP1. 2016 , 79, 775-83	6
550	Targeting the tumour microenvironment in ovarian cancer. 2016 , 56, 131-143	69
549	Ulcerative Colitis. 2016 , 341-368	
548	Macrophages, Inflammation, and Lung Cancer. 2016 , 193, 116-30	137
547	Colitis-Associated Cancer. 2016 ,	0
546	Cancer Surveillance of Patients with Long-Standing Inflammatory Bowel Disease. 2016 , 61-83	
545	Gastrointestinal cancers in inflammatory bowel disease: An update with emphasis on imaging findings. 2016 , 97, 30-46	33
544	The emerging global epidemic of paediatric inflammatory bowel disease--causes and consequences. 2016 , 279, 241-58	29
543	The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice. 2016 , 5, e1062966	59
542	Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. 2016 , 14, 348-354.e17	17
541	An 18-Year Nationwide Cohort Study on The Association Between Diverticulitis and Colon Cancer. 2017 , 265, 954-959	19
540	M2-like macrophages induce colon cancer cell invasion via matrix metalloproteinases. 2017 , 232, 3468-3480	72
539	ALOX15 as a suppressor of inflammation and cancer: Lost in the link. 2017 , 132, 77-83	23
538	The molecular landscape of colitis-associated carcinogenesis. 2017 , 49, 326-330	22
537	Chemoprevention of colorectal cancer in inflammatory bowel disease. 2017 , 17, 247-255	10
536	Rectal and Colon Cancer: Background and Clinical Evidence. 2017 , 155-169	
535	Chemoprevention of colorectal cancer in ulcerative colitis: digging deep in current evidence. 2017 , 11, 339-347	15

534	Clonal evolution of colorectal cancer in IBD. 2017 , 14, 218-229	77
533	Exploration of Inflammatory Bowel Disease in Mice: Chemically Induced Murine Models of Inflammatory Bowel Disease (IBD). 2017 , 7, 13-28	21
532	A case of concomitant colitic cancer and intrahepatic cholangiocarcinoma during follow-up for ulcerative colitis. 2017 , 10, 157-162	1
531	Vitamin D signaling in intestinal innate immunity and homeostasis. 2017 , 453, 68-78	55
530	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. 2017 , 11, 649-670	837
529	Segmental resection is a safe oncological alternative to total proctocolectomy in elderly patients with ulcerative colitis and malignancy. 2017 , 19, 1108-1116	12
528	Dysplasia and colorectal cancer surveillance in inflammatory bowel disease. 2017 , 11, 711-722	15
527	Incidence of Cancer and Screening in Inflammatory Bowel Disease. 2017 , 639-652	
526	Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis. 2017 , 45, 1481-1492	33
525	Diagnosis and management of inflammatory bowel disease in children. 2017 , 357, j2083	49
524	The role of Nrf2-Keap1 axis in colorectal cancer, progression, and chemoresistance. 2017 , 39, 1010428317705519	39
523	Dysplasia and Cancer in Inflammatory Bowel Disease. 2017 , 97, 627-639	17
522	The role of prostatic inflammation in the development and progression of benign and malignant diseases. 2017 , 27, 99-106	34
521	Iron Supplements Modulate Colon Microbiota Composition and Potentiate the Protective Effects of Probiotics in Dextran Sodium Sulfate-induced Colitis. 2017 , 23, 753-766	51
520	Ileal Pouch-Anal Anastomosis for Dysplasia or Cancer Complicating Inflammatory Bowel Disease: Is Total Mesorectal Excision Always Mandatory? An Analysis of 36 Consecutive Patients. 2017 , 11, 936-941	2
519	Measurement of DNA damage in peripheral blood by the γ H2AX assay as predictor of colorectal cancer risk. 2017 , 53, 24-30	14
518	Colon Cancer Screening. 2017 , 283-296	
517	Cancer Risk in 2621 Chinese Patients with Inflammatory Bowel Disease: A Population-based Cohort Study. 2017 , 23, 2061-2068	34

516	Large Registry Epidemiology in IBD. 2017 , 23, 1941-1949	8
515	[Ulcerative Colitis and Adenocarcinoma of the Appendix: Is there a Causal Link?]. 2017 , 142, 1300-1303	
514	Strategies for detecting colon cancer in patients with inflammatory bowel disease. 2017 , 9, CD000279	28
513	Association of Aneuploidy and Flat Dysplasia With Development of High-Grade Dysplasia or Colorectal Cancer in Patients With Inflammatory Bowel Disease. 2017 , 153, 1492-1495.e4	30
512	Regulation of inflammation by microbiota interactions with the host. 2017 , 18, 851-860	318
511	Therapeutic requirements in active ulcerative proctitis: A single-centre study. 2017 , 40, 663-668	4
510	Chronic Pancreatitis and Pancreatic Cancer Risk: A Systematic Review and Meta-analysis. 2017 , 112, 1366-1372	197
509	Danshen improves survival of patients with colon cancer and dihydroisotanshinone I inhibit the proliferation of colon cancer cells via apoptosis and skp2 signaling pathway. 2017 , 209, 305-316	24
508	Endoscopic Surveillance in Long-standing Colitis. 2017 , 15, 429-439	1
507	Inhibition of DMH-DSS-induced colorectal cancer by liposomal bovine lactoferrin in rats. 2017 , 14, 5688-5694	17
506	Tryptophan metabolism along the kynurenine and serotonin pathways reveals substantial differences in colon and rectal cancer. 2017 , 13, 1	16
505	The potential role of platelets in the consensus molecular subtypes of colorectal cancer. 2017 , 36, 273-288	26
504	Chemoprevention of Colorectal Cancer in High-Risk Patients: from Molecular Targets to Clinical Trials. 2017 , 13, 192-204	
503	Epigenetic Changes in Chronic Inflammatory Diseases. 2017 , 106, 139-189	35
502	Prevention of Colorectal Cancer in Inflammatory Bowel Disease Using Advanced Technologies. 2017 , 101-119	
501	Primary Sclerosing Cholangitis. 2017 ,	
500	Low prevalence of dysplastic polyps in patients with ulcerative colitis. 2017 , 41, 204-209	
499	Changing Paradigms in Detection of Dysplasia and Management of Patients With Inflammatory Bowel Disease: Is Colectomy Still Necessary?. 2017 , 152, 440-450.e1	16

- 498 Repression of MicroRNA Function Mediates Inflammation-associated Colon Tumorigenesis. **2017**, 152, 631-643 18
- 497 Colorectal Cancer. **2017**, 1199-1210
- 496 Efficiency of Colorectal Cancer Surveillance in Patients with Ulcerative Colitis: 38 Years' Experience in a Patient Cohort from a Defined Population Area. **2017**, 106, 133-138 6
- 495 Chemotherapy Tolerance and Oncologic Outcomes in Patients With Colorectal Cancer With and Without Inflammatory Bowel Disease. **2017**, 16, e205-e210 11
- 494 Therapeutic requirements in active ulcerative proctitis: A single-centre study. **2017**, 40, 663-668
- 493 Forefront of Medical Care for Children with Inflammatory Bowel Disease. **2017**, 70, 633-644
- 492 Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014. **2017**, 358, j3951 78
- 491 [Effect of Immunomodulators and Biologic Agents on Malignancy in Patients with Inflammatory Bowel Disease]. **2017**, 70, 162-168 1
- 490 The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment. **2016**, 7, 682 54
- 489 Suppression Colitis and Colitis-Associated Colon Cancer by Anti-S100a9 Antibody in Mice. **2017**, 8, 1774 46
- 488 Linking Diet to Colorectal Cancer: The Emerging Role of MicroRNA in the Communication between Plant and Animal Kingdoms. **2017**, 8, 597 6
- 487 Dietary Heme Induces Gut Dysbiosis, Aggravates Colitis, and Potentiates the Development of Adenomas in Mice. **2017**, 8, 1809 71
- 486 The Role of Proinflammatory Pathways in the Pathogenesis of Colitis-Associated Colorectal Cancer. **2017**, 2017, 5126048 70
- 485 Colorectal Malignancy in a Prospective Irish Inflammatory Bowel Disease Population 15 Years Since Diagnosis: Comparison with the EC-IBD Cohort. **2017**, 2017, 4946068 1
- 484 Two Cases of Patients with Ulcerative Colitis Who Developed Neuroendocrine Carcinoma. **2017**, 50, 838-848
- 483 Chronic *Trichuris muris* infection causes neoplastic change in the intestine and exacerbates tumour formation in APC min/+ mice. **2017**, 11, e0005708 16
- 482 Enteropathic Arthritis. **2017**, 1309-1328 0
- 481 An Update on Surveillance in Ulcerative Colitis. **2018**, 20, 7 8

480	Early onset sporadic colorectal cancer: Worrisome trends and oncogenic features. 2018 , 50, 521-532	38
479	Outcomes of Endoscopic Resections of Large Laterally Spreading Colorectal Lesions in Inflammatory Bowel Disease: a Single United Kingdom Center Experience. 2018 , 24, 1196-1203	15
478	MK2 contributes to tumor progression by promoting M2 macrophage polarization and tumor angiogenesis. 2018 , 115, E4236-E4244	48
477	Dysplasia in Inflammatory Bowel Disease: Historical Review, Critical Histopathological Analysis, and Clinical Implications. 2018 , 24, 1895-1903	8
476	Coexistent Solid Malignancies in Pemphigus: A Population-Based Study. 2018 , 154, 435-440	22
475	Detecting dysplasia using white light endoscopy or chromoendoscopy in ulcerative colitis patients without primary sclerosing cholangitis: A systematic review and meta-analysis. 2018 , 52, 180-188	4
474	Epidemiology and Carcinogenesis of Rectal Cancer. 2018 , 19-35	
473	When Do You Start and When Do You Stop Screening for Colon Cancer in Inflammatory Bowel Disease?. 2018 , 16, 621-623	6
472	Reduced Risk of Inflammatory Bowel Disease-associated Colorectal Neoplasia with Use of Thiopurines: a Systematic Review and Meta-analysis. 2018 , 12, 546-558	29
471	Incidence of Colorectal Cancer and Extracolonic Cancers in Veteran Patients With Inflammatory Bowel Disease. 2018 , 24, 617-623	22
470	Multi Matrix System Mesalazine Plus Rectal Mesalazine in the Treatment of Mild to Moderately Active Ulcerative Proctitis. 2018 , 36, 130-135	3
469	Colitis ulcerosa. 2018 , 22, 1-8	
468	Malignancy and Mortality in Pediatric-onset Inflammatory Bowel Disease: A Systematic Review. 2018 , 24, 732-741	19
467	Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. 2018 , 16, 343-356.e3	161
466	Intestinal and Extraintestinal Cancers Associated With Inflammatory Bowel Disease. 2018 , 17, e29-e37	25
465	The epigenetic modifier PBRM1 restricts the basal activity of the innate immune system by repressing retinoic acid-inducible gene-I-like receptor signalling and is a potential prognostic biomarker for colon cancer. 2018 , 244, 36-48	22
464	Bronchioloalveolar lung tumors induced in mice only by non-genotoxic chemicals are not useful for quantitative assessment of pulmonary adenocarcinoma risk in humans. 2018 , 2, 239784731881661	
463	Verbascoside: Identification, Quantification, and Potential Sensitization of Colorectal Cancer Cells to 5-FU by Targeting PI3K/AKT Pathway. 2018 , 8, 16939	26

462	Can we use interleukin-1 β blockade for lung cancer treatment?. 2018 , 7, S160-S164	15
461	Chemoprophylaxis in Colorectal Cancer: Can Prevention be Better than Cure?. 2018 , 14,	
460	Radiation Therapy in Colon Carcinoma. 2018 , 1-15	
459	Gut reaction. 2018 , 563, S34-S35	14
458	Do Androgens Modulate the Pathophysiological Pathways of Inflammation? Appraising the Contemporary Evidence. 2018 , 7,	49
457	The rectal remnant after total colectomy for colitis - intra-operative, post-operative and longer-term considerations. 2018 , 53, 1443-1452	3
456	Differential role of CXCR3 in inflammation and colorectal cancer. 2018 , 9, 17928-17936	16
455	[Updated S3-Guideline Colitis ulcerosa. German Society for Digestive and Metabolic Diseases (DGVS) - AWMF Registry 021/009]. 2018 , 56, 1087-1169	35
454	From Colitis to Cancer: An Evolutionary Trajectory That Merges Maths and Biology. 2018 , 9, 2368	22
453	Use of Curcumin in Achieving Clinical and Endoscopic Remission in Ulcerative Colitis: A Systematic Review and Meta-analysis. 2018 , 356, 350-356	22
452	Obesity Is Associated with Early Onset of Gastrointestinal Cancers in California. 2018 , 2018, 7014073	13
451	Early detection of ulcerative colitis-associated colorectal cancer. 2018 , 6, 83-92	22
450	Updates in colorectal cancer screening in inflammatory bowel disease. 2018 , 34, 208-216	7
449	DNA content analysis of colorectal serrated lesions detects an aneuploid subset of inflammatory bowel disease-associated serrated epithelial change and traditional serrated adenomas. 2018 , 73, 464-472	16
448	Ornithine Decarboxylase in Macrophages Exacerbates Colitis and Promotes Colitis-Associated Colon Carcinogenesis by Impairing M1 Immune Responses. 2018 , 78, 4303-4315	31
447	3-(1H-Benzo[<i>c</i>]imidazol-6-yl)-5-(4-fluorophenyl)-1,2,4-oxadiazole (DDO7232), a Novel Potent Nrf2/ARE Inducer, Ameliorates DSS-Induced Murine Colitis and Protects NCM460 Cells against Oxidative Stress via ERK1/2 Phosphorylation. 2018 , 2018, 3271617	6
446	What can we learn from top-cited articles in inflammatory bowel disease? A bibliometric analysis and assessment of the level of evidence. 2018 , 8, e021233	7
445	Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN. 2018 , 48, 523-537	24

444	Montelukast, a CysLT1 receptor antagonist, reduces colon cancer stemness and tumor burden in a mouse xenograft model of human colon cancer. 2018 , 437, 13-24	18
443	Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. 2018 , 67, 414-430	37
442	New Methylation Biomarker Panel for Early Diagnosis of Dysplasia or Cancer in High-Risk Inflammatory Bowel Disease Patients. 2018 , 24, 2555-2564	10
441	Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota. 2018 , 20, 721-733	47
440	Dro1/Ccdc80 inactivation promotes AOM/DSS-induced colorectal carcinogenesis and aggravates colitis by DSS in mice. 2018 , 39, 1176-1184	6
439	Dysplasia Surveillance in Inflammatory Bowel Disease. 2019 , 435-445.e3	
438	Evolutionary history of human colitis-associated colorectal cancer. 2019 , 68, 985-995	55
437	Changes in the rate of and trends in colectomy for ulcerative colitis during the era of biologics and calcineurin inhibitors based on a Japanese nationwide cohort study. 2019 , 49, 1066-1073	15
436	Mutation Spectrum of Cancer-Associated Genes in Patients With Early Onset of Colorectal Cancer. 2019 , 9, 673	17
435	Omega-3 Polyunsaturated Fatty Acids and Their Bioactive Metabolites in Gastrointestinal Malignancies Related to Unresolved Inflammation. A Review. 2019 , 10, 852	18
434	BRG1 attenuates colonic inflammation and tumorigenesis through autophagy-dependent oxidative stress sequestration. 2019 , 10, 4614	29
433	Simple and Simply the Best? Dublin in the European Spotlight. 2019 , 13, 1363-1364	
432	Can Nrf2 Modulate the Development of Intestinal Fibrosis and Cancer in Inflammatory Bowel Disease?. 2019 , 20,	14
431	British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. 2019 , 68, s1-s106	557
430	Colorectal cancer in inflammatory bowel disease: review of the evidence. 2019 , 23, 3-13	79
429	Colitis-associated colorectal adenocarcinomas are frequently associated with non-intestinal mucin profiles and loss of SATB2 expression. 2019 , 32, 884-892	9
428	Predictive models of disease burden at diagnosis in persons with adult-onset ulcerative colitis using health administrative data. 2019 , 19, 13	1
427	Cancer Screening in Inflammatory Bowel Disease. 2019 ,	

- 426 Indirect oxidative stress from pulmonary inflammation exceeds direct oxidative stress from chemical damage to mitochondria. **2019**, 3, 239784731984284
- 425 Management of Inflammatory Bowel Disease-Associated Dysplasia in the Modern Era. **2019**, 29, 531-548 5
- 424 UC Surveillance. **2019**, 155-167
- 423 Progressing from Recurring Tissue Injury to Genomic Instability: A New Mechanism of Neutrophil Pathogenesis. **2019**, 38, 747-753 8
- 422 Peptide TNIIA2 Derived from Tenascin-C Contributes to Malignant Progression in Colitis-Associated Colorectal Cancer via α -Integrin Activation in Fibroblasts. **2019**, 20, 10
- 421 Smad7 and Colorectal Carcinogenesis: A Double-Edged Sword. **2019**, 11, 12
- 420 A Role for NF- κ B in Organ Specific Cancer and Cancer Stem Cells. **2019**, 11, 52
- 419 The incidence of cancer and mortality in paediatric onset inflammatory bowel disease in Denmark and Finland during a 23-year period: a population-based study. **2019**, 50, 33-39 20
- 418 Differences in colonic crypt morphology of spontaneous and colitis-associated murine models via second harmonic generation imaging to quantify colon cancer development. **2019**, 19, 428 3
- 417 Protein functionalised self assembled monolayer based biosensor for colon cancer detection. **2019**, 201, 465-473 22
- 416 NOD-like receptor signaling in inflammation-associated cancers: From functions to targeted therapies. **2019**, 64, 152925 36
- 415 Risk of Early Colorectal Cancers Needs to Be Considered in Inflammatory Bowel Disease Care. **2019**, 64, 2273-2279 6
- 414 The Epidemiology of Rectal Cancer. **2019**, 3-20
- 413 DUBLIN [Degree of Ulcerative colitis Burden of Luminal Inflammation] Score, a Simple Method to Quantify Inflammatory Burden in Ulcerative Colitis. **2019**, 13, 1365-1371 11
- 412 Endoscopic detection and resection of dysplasia in inflammatory bowel disease-techniques with videos. **2019**, 34, 569-580 3
- 411 Risk of Malignant Cancers in Inflammatory Bowel Disease. **2019**, 13, 1302-1310 12
- 410 Risk factors for colorectal neoplasia in patients with underlying inflammatory bowel disease: a multicenter study. **2019**, 7, 67-73 3
- 409 Increased nicotinamide adenine dinucleotide pool promotes colon cancer progression by suppressing reactive oxygen species level. **2019**, 110, 629-638 27

408	Colorectal Cancer in Ulcerative Colitis: Surveillance. 2019 , 258-270	
407	Systematic review with meta-analysis: Chromoendoscopy versus white light endoscopy in detection of dysplasia in patients with inflammatory bowel disease. 2019 , 20, 206-214	5
406	Network-Based Combinatorial CRISPR-Cas9 Screens Identify Synergistic Modules in Human Cells. 2019 , 8, 482-490	23
405	Surveillance in inflammatory bowel disease: an overview. 2019 , 17, 32-37	
404	Top-100 highest-cited original articles in inflammatory bowel disease: A bibliometric analysis. 2019 , 98, e15718	12
403	Risk of Colorectal Cancer in Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis. 2019 , 2019, 5363261	20
402	Rates and characteristics of postcolonoscopy colorectal cancer in the Swedish IBD population: what are the differences from a non-IBD population?. 2019 , 68, 1588-1596	13
401	Endoscopic Submucosal Dissection in Patients with Ulcerative Colitis. 2019 , 99, 27-32	1
400	Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response. 2019 , 10, 38	98
399	21 Colon Carcinoma: Epidemiology, Etiology, Pathology, and Diagnosis. 2019 ,	
398	Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis. 2019 , 64, 740-750	10
397	ErbB4 acts as a suppressor in colitis and its associated carcinoma by negatively regulating cholesterol metabolism. 2019 , 40, 680-686	2
396	Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement from the Global Interventional IBD Group. 2019 , 89, 215-237	37
395	Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS). 2019 , 57, 162-241	25
394	Solitary extramedullary plasmacytoma of the rectum complicating ulcerative colitis. 2019 , 12, 160-165	2
393	Promoter methylation cooperates with SNPs to modulate transcription and alter UC risk. 2019 , 17, 17-22	2
392	Management of Ulcerative Colitis in the Elderly. 2019 , 36, 13-27	3
391	Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study. 2019 , 68, 414-422	70

390	Role of the IL-33/ST2L axis in colorectal cancer progression. 2019 , 343, 103740	16
389	Colitis, Ulcerative (Pediatric). 2020 , 575-586	
388	The role of polyamines in the regulation of macrophage polarization and function. 2020 , 52, 151-160	37
387	Prediagnostic circulating inflammation biomarkers and esophageal squamous cell carcinoma: A case-cohort study in Japan. 2020 , 147, 686-691	9
386	Performance measures in inflammatory bowel disease surveillance colonoscopy: Implementing changes to practice improves performance. 2020 , 32, 592-599	1
385	Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. 2020 , 395, 123-131	113
384	Proprotein convertases: Key players in inflammation-related malignancies and metastasis. 2020 , 473, 50-61	18
383	Endoscopic management of inflammatory bowel disease-associated complications. 2020 , 36, 33-40	2
382	Molecular systems in inflammatory bowel disease. 2020 , 367-388	1
381	Nonconventional dysplasia in patients with inflammatory bowel disease and colorectal carcinoma: a multicenter clinicopathologic study. 2020 , 33, 933-943	20
380	How to manage IBD in the 'elderly'. 2020 , 11, 468-477	5
379	Colorectal Cancer. 2020 , 1219-1280.e15	3
378	Escherichia coli K12 Upregulates Programmed Cell Death Ligand 1 (PD-L1) Expression in Gamma Interferon-Sensitized Intestinal Epithelial Cells via the NF- κ B Pathway. 2020 , 89,	4
377	Extraintestinal Manifestations and Other Comorbidities in Ulcerative Colitis and Crohn Disease: A Danish Nationwide Registry Study 2003-2016. 2020 , 2,	4
376	Endoscopic visualization of cancer and dysplasia in patients with ulcerative colitis following sensitization with oral 5-aminolevulinic acid. 2020 , 21, 498-504	2
375	Cancer Risk in Pediatric-Onset Inflammatory Bowel Disease. 2020 , 8, 400	7
374	The Importance of Hypoxia-Inducible Factors (HIF-1 and HIF-2) for the Pathophysiology of Inflammatory Bowel Disease. 2020 , 21,	11
373	Myosins: Driving us towards novel targets and biomarkers in cancer. 2020 , 356, 291-322	

372	Ulcerative Colitis-Derived Colonoid Culture: A Multi-Mineral-Approach to Improve Barrier Protein Expression. 2020 , 8, 577221	4
371	Endoscopic and histologic activity assessment considering disease extent and prediction of treatment failure in ulcerative colitis. 2020 , 55, 1157-1162	2
370	Risk factors for ulcerative colitis-associated colorectal cancer: A retrospective cohort study. 2020 , 99, e21686	3
369	High neutrophil-lymphocyte ratio is not independently associated with worse survival or recurrence in patients with extremity soft tissue sarcoma. 2020 , 168, 760-767	
368	Heading in the Right Dissection: Toward an Endoscopic Cancer Cure in a Patient with Long-Standing Ulcerative Colitis. 2020 , 65, 2818-2822	
367	The Influence of Microbial Metabolites in the Gastrointestinal Microenvironment on Anticancer Immunity. 2020 ,	1
366	Risk of Colon Cancer and Recommended Surveillance Strategies in Patients with Ulcerative Colitis. 2020 , 49, 791-807	10
365	Malignancies in Inflammatory Bowel Disease. 2020 , 101 Suppl 1, 136-145	17
364	Gut Microbiome and Its Impact on Health and Diseases. 2020 ,	1
363	Deficiency of activation-induced cytidine deaminase in a murine model of ulcerative colitis. 2020 , 15, e0239295	1
362	Sex matters: impact on pathogenesis, presentation and treatment of inflammatory bowel disease. 2020 , 17, 740-754	15
361	Endoscopic surveillance of colorectal cancer in inflammatory bowel diseases: a review of the literature. 2020 , 20, 851-863	2
360	Does IBD Portend Worse Outcomes in Patients with Rectal Cancer? A Case-Matched Analysis. 2020 , 63, 1265-1275	1
359	Influence of MIF polymorphisms on CpG island hyper-methylation of CDKN2A in the patients with ulcerative colitis. 2020 , 21, 201	2
358	Effect of ambient air pollution on the incidence of colorectal cancer among a diabetic population: a nationwide nested case-control study in Taiwan. 2020 , 10, e036955	3
357	Incidence, Risk Factors and Outcomes of Cancer of the Anal Transitional Zone in Patients with Ulcerative Colitis. 2020 , 14, 1565-1571	3
356	KRAS amplification in metastatic colon cancer is associated with a history of inflammatory bowel disease and may confer resistance to anti-EGFR therapy. 2020 , 33, 1832-1843	8
355	Diagnosis and management of inflammatory bowel disease-associated neoplasia: considerations in the modern era. 2020 , 13, 1756284820920779	6

354	Metabolic and immunologic control of intestinal cell function by mTOR. 2020 , 32, 455-465	3
353	Epithelial Toll-like receptors and their role in gut homeostasis and disease. 2020 , 17, 263-278	118
352	The Complex Interplay Between Inflammatory Bowel Disease and Malignancy. 2020 , 22, 13	4
351	Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes. 2020 , 14, 1345-1353	5
350	Xinhuang Tablets Improve Intestinal Barrier Function via Regulating Epithelial Tight Junctions in Dextran Sulfate Sodium-Induced Ulcerative Colitis Mice. 2021 , 24, 33-39	4
349	Non-conventional dysplasia in inflammatory bowel disease is more frequently associated with advanced neoplasia and aneuploidy than conventional dysplasia. 2021 , 78, 814-830	5
348	Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study. 2021 , 87, 1141-1149	
347	Risk of Cancers in Patients with Pediatric Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. 2021 , 229, 102-117.e36	1
346	Epithelial TLR4 Signaling Activates DUOX2 to Induce Microbiota-Driven Tumorigenesis. 2021 , 160, 797-808.e6	11
345	Risk of renal cancer in patients with inflammatory bowel disease: A pooled analysis of population-based studies. 2021 , 39, 93-99	0
344	Colorectal cancer in Crohn's colitis is associated with advanced tumor invasion and a poorer survival compared with ulcerative colitis: a retrospective dual-center study. 2021 , 36, 141-150	3
343	Ulcerative Colitis in Children and Adolescents. 2021 , 474-492.e8	0
342	Real-World Experience of Endoscopic Submucosal Dissection for Ulcerative Colitis-Associated Neoplasia. 2021 , 6, 70-77	3
341	The Ugly Duckling of Thiopurines Becomes the Beautiful Swan of Colitis-associated Cancer Management. 2021 , 11, 297-298	
340	Ulcerative Colitis Diagnosis and Management: Past, Present, and Future Directions. 2021 , 61-88	0
339	Somatic mutation profiles as molecular classifiers of ulcerative colitis-associated colorectal cancer. 2021 , 148, 2997-3007	4
338	A case-control study examining the association of smad7 and TLR single nucleotide polymorphisms on the risk of colorectal cancer in ulcerative colitis. 2021 , 23, 1043-1048	3
337	Treatment and outcome of ulcerative colitis during the first 10 years after diagnosis in a prospectively followed population-based cohort. 2021 , 56, 403-409	1

- 336 TNF- α gene polymorphisms and risk of urinary bladder cancer: A case-control study and meta-analysis. **2021**, 27, 100848
- 335 Suppression of ELF4 in ulcerative colitis predisposes host to colorectal cancer. **2021**, 24, 102169 1
- 334 Non-conventional dysplastic subtypes in inflammatory bowel disease: a review of their diagnostic characteristics and potential clinical implications. **2021**, 55, 83-93 0
- 333 The Western Dietary Pattern Combined with Vancomycin-Mediated Changes to the Gut Microbiome Exacerbates Colitis Severity and Colon Tumorigenesis. **2021**, 13, 3
- 332 Genetic Pathogenesis of Inflammation-Associated Cancers in Digestive Organs. **2021**, 10, 1
- 331 Adiponectin and the Control of Metabolic Dysfunction: Is Exercise the Magic Bullet?. **2021**, 12, 651732 2
- 330 Inflammatory Conditions of the Colon. **2021**, 235-305
- 329 A Case of Squamous Cell Carcinoma of the Anal Canal Associated with Ulcerative Colitis. **2021**, 54, 351-358
- 328 Evaluation of the efficacy of MMX mesalazine therapy for moderate ulcerative colitis. **2021**, 113-123 1
- 327 Predicting Colorectal Cancer Occurrence in IBD. **2021**, 13, 3
- 326 Recommendations of the Spanish Working Group on Crohn's disease and Ulcerative Colitis (Grupo Espa l de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa - GETECCU) on dysplasia screening in inflammatory bowel disease patients. **2021**, 44, 435-447 0
- 325 Recommendations of the Spanish Working Group on Crohn's disease and Ulcerative Colitis (Grupo Espa l de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa - GETECCU) on dysplasia screening in inflammatory bowel disease patients. **2021**, 44, 435-447
- 324 Hypermucinous, Goblet Cell Deficient, and Crypt Cell Dysplasias in Inflammatory Bowel Disease are Often Associated with Flat/Invisible Endoscopic Appearance and Advanced Neoplasia on Follow-Up. **2021**, 2
- 323 The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Ulcerative Colitis. **2021**, 64, 783-804 2
- 322 The Significance of Flat/Invisible Dysplasia and Nonconventional Dysplastic Subtypes in Inflammatory Bowel Disease: A Review of Their Morphologic, Clinicopathologic, and Molecular Characteristics. **2022**, 29, 15-24 0
- 321 The bifurcated role of adiponectin in colorectal cancer. **2021**, 278, 119524 0
- 320 Epidemiology of Colorectal Cancer in Inflammatory Bowel Disease - the Evolving Landscape. **2021**, 23, 16 4
- 319 A case of appendix adenocarcinoma associated with ulcerative colitis. **2021**, 9, e04768

318	The Macrophage Iron Signature in Health and Disease. 2021 , 22,	3
317	Management of Dysplasia in Ulcerative Colitis. 2021 , 31, 855-860	
316	Involvement of integrin-activating peptides derived from tenascin-C in colon cancer progression. 2021 , 13, 980-994	1
315	AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review. 2021 , 161, 1043-1051.e4	6
314	Inflammatory bowel disease and colon cancer. 1992 , 70, 1313-1316	39
313	Completion proctectomy in ulcerative colitis. 1997 , 84, 436-7	6
312	Colon, Rectum, and Anus. 2003 , 281-323	1
311	Molecular mechanisms of human carcinogenesis. 2006 , 321-49	17
310	Colorectal Cancer: Epidemiology. 2009 , 5-25	1
309	The Pathology of Chronic Inflammatory Bowel Disease. 241-262	1
308	Genetic Instability and Chronic Inflammation in Gastrointestinal Cancers. 2010 , 351-397	1
307	Chemoprevention of Chronic Inflammatory Bowel Disease-Induced Carcinogenesis in Rodent Models by Berries. 2011 , 227-243	1
306	Restorative Proctocolectomy with Ileoanal Anastomosis. 1999 , 173-185	3
305	Do leukotrienes increase cell viability in human intestinal epithelial cells?. 2002 , 507, 193-8	1
304	Induction of leukotriene B4 metabolism by cancer chemopreventive agents. 1999 , 469, 599-605	4
303	Epidemiological Trends in Colorectal Cancer. 2002 , 23-46	1
302	Inflammatory bowel disease: a model of chronic inflammation-induced cancer. 2009 , 511, 193-233	33
301	Acquired risk factors for colorectal cancer. 2009 , 472, 361-72	35

300	Potential of p38 MAP kinase inhibitors in the treatment of cancer. 2003 , 60, 59-92	23
299	Ulcerative Proctitis and Anorectal Crohn's Disease. 2019 , 531-554	1
298	Colorectal Cancer in Inflammatory Bowel Disease. 2004 , 160-166	2
297	Colon, Rectum, and Anus. 2001 , 667-762	3
296	Kolon- und Rektumkarzinom. 2004 , 875-932	1
295	Molecular Alterations in Inflammatory Colonic Carcinogenesis and Markers for Detecting Colitis-Associated Cancer. 2016 , 85-105	1
294	Gastrointestinal tract. 2011 , 585-816	1
293	Free Radicals in Gastrointestinal and Hepatic Disease. 1995 , 143-174	1
292	Inflammatory Bowel Disease. 2012 , 243-264	1
291	Colorectal Cancer. 2014 , 1278-1335.e14	1
290	Aktualisierte S3-Leitlinie Colitis ulcerosa [Living Guideline. 2020 , 58, e241-e326	6
289	Perspectives on endoscopic surveillance of dysplasia in inflammatory bowel disease: a survey of academic gastroenterologists. 2017 , 5, E974-E979	11
288	Polypoid dysplasia and adenomas in inflammatory bowel disease: a clinical, pathologic, and follow-up study of 89 polyps from 59 patients. 1998 , 22, 275-84	151
287	Intestinal adenocarcinoma in Crohn's disease: a report of 30 cases with a focus on coexisting dysplasia. 1999 , 23, 651-5	108
286	Prevalence and relative risk of malignancy in relatives of inflammatory bowel disease patients and control subjects. 1998 , 27, 211-4	10
285	Ulcerative colitis complicated by dysplasia-adenoma-carcinoma in a man with Bloom's syndrome. 1999 , 28, 380-2	5
284	Colonoscopic surveillance for cancer in ulcerative colitis: a critical review. 1997 , 24, 202-10	29
283	Colorectal cancer screening: today and tomorrow. 2006 , 99, 240-6; quiz 247-9	6

282	Elevated c-Src tyrosine kinase activity in premalignant epithelia of ulcerative colitis. 1994 , 93, 509-15	106
281	The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. 2003 , 112, 1887-94	146
280	Tumbling down a different pathway to genetic instability. 2003 , 112, 1793-1795	25
279	Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK. 2013 , 123, 1428-43	80
278	mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. 2013 , 123, 767-81	69
277	The deubiquitinase USP9X regulates FBW7 stability and suppresses colorectal cancer. 2018 , 128, 1326-1337	49
276	The Degree of Ulcerative Colitis Burden of Luminal Inflammation score is superior to predicting medium- to long-term prognosis in patients with active ulcerative colitis. 2020 , 13, 1756284820981210	3
275	Leukotriene D4 activates MAPK through a Ras-independent but PKC γ -dependent pathway in intestinal epithelial cells. 2002 , 115, 1883-1893	74
274	Regulation of cysteinyl leukotriene receptor 2 expression--a potential anti-tumor mechanism. 2011 , 6, e29060	10
273	Macrophages, nitric oxide and microRNAs are associated with DNA damage response pathway and senescence in inflammatory bowel disease. 2012 , 7, e44156	46
272	A20 restricts wnt signaling in intestinal epithelial cells and suppresses colon carcinogenesis. 2013 , 8, e62223	33
271	COX-2-765G>C polymorphism increases the risk of cancer: a meta-analysis. 2013 , 8, e73213	16
270	Use of thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel diseases: a meta-analysis. 2013 , 8, e81487	35
269	Stool phospholipid signature is altered by diet and tumors. 2014 , 9, e114352	12
268	MDR1A deficiency restrains tumor growth in murine colitis-associated carcinogenesis. 2017 , 12, e0180834	4
267	PPAR α and PGE signaling pathways communicate and connect inflammation to colorectal cancer. 2014 , 1,	16
266	Hormone receptor expression of colorectal cancer diagnosed during the peri-partum period. 2019 , 8, 1149-1158	2
265	Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate. 2016 , 7, 63226-63241	11

264	Looking for the best anti-colitis medicine: A comparative analysis of current and prospective compounds. 2017 , 8, 228-237	9
263	Inflammatory biomarkers in metastatic colorectal cancer: prognostic and predictive role beyond the first line setting. 2017 , 8, 96048-96061	20
262	Genomic landscape of colitis-associated cancer indicates the impact of chronic inflammation and its stratification by mutations in the Wnt signaling. 2018 , 9, 969-981	23
261	Comprehensive analysis identifying aberrant DNA methylation in rectal mucosa from ulcerative colitis patients with neoplasia. 2018 , 9, 33149-33159	6
260	Radiation and SN38 treatments modulate the expression of microRNAs, cytokines and chemokines in colon cancer cells in a p53-directed manner. 2015 , 6, 44758-80	42
259	Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiation. 2016 , 7, 2159-74	19
258	Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer. 2016 , 29, 127-36	5
257	The mutator phenotype in cancer: molecular mechanisms and targeting strategies. 2010 , 11, 1296-303	32
256	Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94. 2016 , 16, 2765-78	55
255	Malignancy Associated with Inflammatory Bowel Disease. 2009 , 25, 150	3
254	Adherence to surveillance guidelines for dysplasia and colorectal carcinoma in ulcerative and Crohn's colitis patients in the Netherlands. 2009 , 15, 226-30	60
253	Colorectal cancer surveillance in inflammatory bowel disease: the search continues. 2009 , 15, 61-6	55
252	A novel mouse model for colitis-associated colon carcinogenesis induced by 1,2-dimethylhydrazine and dextran sulfate sodium. 2004 , 10, 2958-62	31
251	C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer. 2004 , 10, 1115-20	50
250	5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease. 2005 , 11, 309-14	48
249	Magnifying chromoscopy, a novel and useful technique for colonoscopy in ulcerative colitis. 2007 , 13, 2523-8	8
248	5-aminosalicylic acid in combination with nimesulide inhibits proliferation of colon carcinoma cells in vitro. 2007 , 13, 2872-7	6
247	Ileal pouch surgery for ulcerative colitis. 2007 , 13, 3288-300	55

246	Surveillance for colitis-associated colon neoplasia. 2010 , 16, 4646-51	5
245	Pathobiology of the neutrophil-intestinal epithelial cell interaction: role in carcinogenesis. 2010 , 16, 5790-800	44
244	Iron: an emerging factor in colorectal carcinogenesis. 2010 , 16, 663-72	55
243	Intestinal inflammation and colorectal cancer: a double-edged sword?. 2011 , 17, 3092-100	72
242	Clinical, serological and genetic predictors of inflammatory bowel disease course. 2012 , 18, 3806-13	64
241	Colorectal cancer in patients with inflammatory bowel disease: can we predict risk?. 2012 , 18, 4091-4	18
240	Fifteen-year-old colon cancer patient with a 10-year history of ulcerative colitis. 2013 , 19, 2437-40	12
239	Neurotensin receptor 1 overexpression in inflammatory bowel diseases and colitis-associated neoplasia. 2013 , 19, 4504-10	8
238	Has the risk of colorectal cancer in inflammatory bowel disease decreased?. 2013 , 19, 7561-8	63
237	Risk of cancer, with special reference to extra-intestinal malignancies, in patients with inflammatory bowel disease. 2013 , 19, 9359-65	20
236	Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis. 2014 , 20, 4980-6	29
235	Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature. 2014 , 20, 8783-9	39
234	Cysteinyl leukotrienes and their receptors: bridging inflammation and colorectal cancer. 2014 , 20, 968-77	52
233	Butein effects in colitis and interleukin-6/signal transducer and activator of transcription 3 expression. 2015 , 21, 465-74	15
232	From the surface to the single cell: Novel endoscopic approaches in inflammatory bowel disease. 2015 , 21, 11260-72	16
231	Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. 2015 , 21, 1956-71	127
230	Angiopoietin and vascular endothelial growth factor expression in colorectal disease models. 2015 , 21, 2645-50	5
229	Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective. 2016 , 22, 10103-10117	29

228	Detection and characterization of murine colitis and carcinogenesis by molecularly targeted contrast-enhanced ultrasound. 2017 , 23, 2899-2911	5
227	Myo-inositol reduces Eatenin activation in colitis. 2017 , 23, 5115-5126	6
226	Colorectal cancer screening from 45 years of age: Thesis, antithesis and synthesis. 2019 , 25, 2565-2580	26
225	Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments. 2019 , 25, 4148-4157	54
224	Primary T-cell lymphoma of the colon. 1997 , 12, 238-41	13
223	Esophageal cancer research today and tomorrow: Lessons from algae and other perspectives. 2018 , 5, 75-90	6
222	[Recent Advances in Understanding Colorectal Cancer and Dysplasia Related to Ulcerative Colitis]. 2015 , 66, 312-9	2
221	Status of colitis-associated cancer in ulcerative colitis. 2016 , 8, 351-7	45
220	Efficacy of various endoscopic modalities in detecting dysplasia in ulcerative colitis: A systematic review and network meta-analysis. 2020 , 12, 159-171	3
219	Endoscopy in inflammatory bowel disease when and why. 2012 , 4, 201-11	18
218	Statin Exposure Is Not Associated with Reduced Prevalence of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease. 2019 , 13, 54-61	8
217	Risk Factors of Colorectal Stricture Associated with Developing High-Grade Dysplasia or Cancer in Ulcerative Colitis: A Multicenter Long-term Follow-up Study. 2020 , 14, 601-610	5
216	Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey. 2019 , 30, 139-147	4
215	Role of random biopsies in surveillance of dysplasia in ulcerative colitis patients with high risk of colorectal cancer. 2016 , 14, 264-9	12
214	Management of inflammatory bowel disease in older persons: evolving paradigms. 2018 , 16, 194-208	15
213	Advanced neoplasia detection using chromoendoscopy and white light colonoscopy for surveillance in patients with inflammatory bowel disease. 2020 , 18, 438-446	1
212	Colorectal dysplasia in chronic inflammatory bowel disease: pathology, clinical implications, and pathogenesis. 2010 , 134, 876-95	61
211	Colon cancer screening and surveillance in inflammatory bowel disease. 2014 , 47, 509-15	26

- 210 Endoscopic Therapeutic Approach for Dysplasia in Inflammatory Bowel Disease. **2017**, 50, 437-445 4
- 209 Inflammatory Bowel Disease and Risk of Colorectal Cancer: An Overview From Pathophysiology to Pharmacological Prevention. **2021**, 12, 772101 4
- 208 Inflammatory bowel disease in the elderly. **2000**, 96-104
- 207 Oncology. **2000**, 653-672
- 206 Inflammatory Bowel Disease in the Elderly. **2001**, 609-619 2
- 205 The Causes of Colorectal Cancer. **2002**, 1-22
- 204 Pathogenesis of Colorectal Cancer. **2002**, 23-48
- 203 The Evolutionary Pattern of Primary Sclerosing Cholangitis: From a Benign to Severe Disease. **2002**, 67-84
- 202 Colorectal Cancer Screening and Surveillance. **2002**, 95-115
- 201 Dysplasia in inflammatory bowel disease: clinical pathology and current surveillance methods. **2003**, 719-729
- 200 Inflammatory Diseases of the Colon, Rectum, Anus and Perianal Region. **2003**, 335-398
- 199 Bewährte und neue diagnostische Strategien zur Früherkennung intestinaler Dysplasien und Neoplasien. **2003**, 65-73
- 198 Entzündliche Erkrankungen des Dickdarms, Anorektums und Perianalbereichs. **2003**, 347-416
- 197 Colitis in Childhood. **2004**, 100-127
- 196 Colitis, Ulcerative (Pediatric). **2004**, 400-408
- 195 Nitric oxide-donating aspirins spare the gastrointestinal (GI) system and improve the treatment of inflammation-related GI and cardiovascular pathologies. **2004**, 93-108
- 194 Inducible Nitric Oxide Synthase as a Target for Chemoprevention. **2004**, 133-151 1
- 193 Chronischentzündliche Darmerkrankungen: Morbus Crohn und Colitis ulcerosa. **2006**, 533-553

192 Detecting dysplasias in ulcerative colitis. **2006**, 104-107

191 Colitis ulcerosa. **2006**, 462-464

190 Ulcerative Colitis. **2006**, 1462-1474

0

189 Chirurgische Onkologie. **2006**, 179-202

188 A Case of Colon Cancer Associated with Colonic Tuberculosis. **2007**, 23, 194

187 Colon, Rectum, and Anus. **2008**, 1011-1110

1

186 Colitic Cancer with a Variety of Pathologies Arising in Ulcerative Colitis Patients-A Case Report. **2008**, 61, 267-271

3

185 Patients at risk for colorectal cancer in inflammatory bowel disease. **2009**, 92-96

184 Inflammatory Bowel Disease. **2009**, 379-392

183 A CASE OF ADVANCED COLITIC CANCER FOUND TWO YEARS AFTER SURVEILLANCE COLONOSCOPY. **2009**, 70, 802-807

1

182 Can we predict the natural history of ulcerative colitis?. **2009**, 38-45

181 16 Colonicarcinoom. **2009**, 191-202

180 Cancer in inflammatory bowel disease: is there a chance for cancer prevention?. **2009**, 97-106

179 Oral budesonide for induction of remission in ulcerative colitis.

178 Update for Indeterminate Colitis. **2010**, 26, 165

177 Ulcerative Colitis: Definition and General Description. **2010**, 378-380

176 Sclerosing Cholangitis and Recurrent Pyogenic Cholangitis. **2010**, 1153-1170.e6

175 Colorectal Cancer in Ulcerative Colitis: Surveillance. **2010**, 301-310

- 174 MICI et cancers de l'intestin. **2011**, 139-147 1
- 173 Surgery for Inflammatory Bowel Disease in the Elderly. **2011**, 837-855
- 172 Diagnosis and Management of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease. **2012**, 701-711
- 171 Surveillance Colonoscopy in UC: What is the Best Way to do it?. 57-60
- 170 Is Anti-TNF Therapy Safe to Use in People with a History of Malignancy?. 136-139
- 169 Colorectal Cancer Screening and Surveillance. **2012**, 458-466
- 168 Inflammatory Bowel Disease Associated Colorectal Neoplasia. **2012**, Suppl 8, 002
- 167 The various mechanisms of Korean traditional medicines for anti-cancer. **2012**, 27, 39-55 1
- 166 Malignant Tumors Arising in Inflammatory Bowel Disease. **2013**, 531-545
- 165 The Pathology of Chronic Inflammatory Bowel Disease. **2013**, 223-239
- 164 Inflammation, Chronic Disease, and Cancer: Is Psychological Distress the Common Thread?. **2013**, 13-30
- 163 Dysplasia in Inflammatory Bowel Disease. **2013**, 213-224
- 162 Enteropathic Arthritis. **2013**, 1251-1268
- 161 Inflammatory Bowel Disease. **2013**, 1961-1981
- 160 Histopathology analysis of benign colorectal diseases and colorectal cancer in Hatyai Hospital, Songkhla, Thailand. **2013**, 14, 2667-71 4
- 159 Inflammation-Induced Esophageal and Colon Adenocarcinoma Formation in Animal Models. **2013**, 41-54
- 158 Mimics of Ulcerative Colitis. **2014**, 393-403
- 157 How to Find and Apply Large Databases for Epidemiologic Research. 83-97

156 The Natural History of Ulcerative Colitis. **2014**, 23-30

155 Chemoprevention in Ulcerative Colitis. **2014**, 291-296

154 Colitis in Infancy and Childhood. **2014**, 197-248

1

153 Colorectal Cancer. **2014**, 1-13

152 Small Bowel Adenocarcinoma in Association with Ulcerative Colitis: A Case Report. **2014**, 75, 479-483

151 Maligne Tumoren bei chronischentzündlichen Darmerkrankungen. **1993**, 86-100

150 Cancer risk in IBD. **1994**, 277-282

149 Chronic Pancreatitis and Pancreatic Cancer: Are They Related?. **1994**, 498-504

148 COLON CANCER SURVEILLANCE. **1995**, 24, 671-687

9

147 Maligne Tumoren bei chronischentzündlichen Darmerkrankungen. **1996**, 100-115

146 Screening for Colorectal Tumors. **1996**, 287-334

145 Colonoscopy in ileocolitis. **1997**, 317-329

144 Onkologische Aspekte der chirurgischen Therapie der Colitis ulcerosa. **1998**, 441-446

143 Surgical Pathology. **1999**, 47-93

142 Dysplasia and Cancer. **1999**, 246-255

1

141 Endoscopic Surveillance for Neoplasia in IBD: Random Biopsy. **2015**, 237-250

140 Spatial modeling of colonic lesions with geographic information systems. **2015**, 17, e18129

139 Ulcerative colitis with inflammatory polyposis in a teenage boy: a case report. **2015**, 21, 1044-8

0

138 Chronisch-entzündliche Darmerkrankungen. **2015**, 277-296

137 Chemopreventive effect of Eviniferin in azoxymethane-induced mouse colorectal tumor and Caco-2 cells. **2015**, 16, 60-66

136 Neoplasia of the Gastrointestinal Tract. 587-616

135 Colitis-Associated Cancer: Overview. **2016**, 1-19

134 Incidence and Risk Factors. **2016**, 23-39

133 Prevention and Prognosis. **2016**, 41-57

132 Primary Sclerosing Cholangitis-Associated Inflammatory Bowel Disease. **2017**, 29-40

0

131 Carcinogenic and stem cell-like phenotypes of Smad2/3 linker phosphorylation in a mouse model of colitis-associated colorectal cancer. **2017**, 68, 17-22

130 The Pathology of Chronic Inflammatory Bowel Disease. **2017**, 273-286

129 A Case of a 14-year-old Girl with Colitic Cancer who Underwent Laparoscopic Total Colectomy Safely. **2017**, 78, 809-813

1

128 Malignant Tumors Arising in Inflammatory Bowel Disease. **2017**, 669-683

127 MULTIFOCAL SYNCHRONOUS SIGNET RING CELL CARCINOMA IN ULCERATIVE COLITIS- AN UNCOMMON PRESENTATION. **2017**, 6, 1831-1832

126 Inflammatory bowel disease as a risk factor for colorectal cancer. **2017**, 19, 232-236

125 A Taiwanese population-based study on the association between chronic tonsillitis and tonsil cancer. **2018**, 9, 7644-7650

1

124 Cancer Risk and Screening in Pediatric Patients. **2019**, 119-130

123 Promoter Methylation Alters the UC Risk by Regulating RAGE Expression. **2019**, 09, 88-95

122 Operative Therapy for Ulcerative Colitis. **2019**, 1919-1940

121 Epidemiology and Risk Factors for Colorectal Cancer in Inflammatory Bowel Diseases. **2019**, 1-15

1

120	Historia badań nad rolą zapalenia w onkologii. 2019 , 16, 1-6	0
119	Microcarcinoid and Ulcerative Colitis: Case Report and Literature Review. 2020 , 12, e8803	2
118	Expression of Oncogenic Molecules in Pediatric Ulcerative Colitis. 2021 , 1-9	0
117	Surgery, cancer and mortality among patients with ulcerative colitis diagnosed 1962-1987 and followed until 2017 in a Danish population-based inception cohort. 2021 ,	2
116	Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management. 2021 ,	16
115	Maintains Genome Stability in Ulcerative Colitis Regulating Anaphase-Promoting Complex Subunit 7. 2021 , 12, 761113	1
114	Detection of colonic dysplasia in patients with ulcerative colitis. 2020 , 9, 68	
113	Risk of solid malignancies in bullous pemphigoid: A large-scale population-based cohort study. 2021 , 48, 317-323	0
112	STUDY OF PATTERNS OF DYSPLASIA IN INFLAMMATORY BOWEL DISEASES. 2020 , 1-3	
111	Biomarkers for Early Detection of Colitis-associated Colorectal Cancer - Current Concepts, Future Trends. 2021 , 22, 137-145	2
110	Disposable free three port laparoscopic appendectomy ¶low cost alternative for emergency. 2020 , 11, 94-98	
109	Colorectal Cancer. 2020 , 661-672	
108	Role of Gut Microbiome in Colorectal Cancer. 2020 , 153-165	
107	Excellent Outcomes After Extended Radical Pelvic Resection for Locally Advanced and Recurrent IBD-Associated Anorectal Cancer. 2021 , 64, 209-216	1
106	High PGD receptor 2 levels are associated with poor prognosis in colorectal cancer patients and induce VEGF expression in colon cancer cells and migration in a zebrafish xenograft model. 2021 ,	0
105	Risk Factors for Colorectal Cancer Susceptibility. 2005 , 67-84	
104	A case of refractory proctitis. 243-248	
103	Predicting the natural history of inflammatory bowel disease. 63-69	

102 Indications for Surgical Treatment of Ulcerative Colitis. **2006**, 239-249

101 Follow-Up of Restorative Proctocolectomy: Clinical Experience of a Specialised Pouch Clinic. **2006**, 293-300

100 Malignant Tumors Arising in Inflammatory Bowel Disease. **2008**, 611-630

99 Colorectal cancer in patients with inflammatory bowel disease: influence of nutritional habits and environmental clues. 3-16

98 Can we prevent inflammatory bowel disease-related colorectal cancer with 5-aminosalicylic acid, azathioprine, or 6-mercaptopurine? The clinical evidence. 193-200

97 Inflammatory bowel disease high-risk groups. 17-24

96 Mesalazine and cell cycle progression. 236-243

95 Tumbling down a different pathway to genetic instability. **2003**, 112, 1793-5

9

94 Endoscopic Colon Surveillance. **2006**, 215-227

93 Colorectal Cancer Screening and Surveillance. **2007**, 51-68

92 Kolorektales Karzinom. 747-817

91 Colonic adenocarcinoma following total colectomy and abdomino-perineal resection for ulcerative colitis. **2021**, 91, 1313-1315

90 Elective staged proctocolectomy and living donor liver transplantation for colon cancer with sclerosing cholangitis-related ulcerative colitis: a case report. **2020**, 6, 278

89 Periodic health examination, 1994 update: 2. Screening strategies for colorectal cancer. Canadian Task Force on the Periodic Health Examination. **1994**, 150, 1961-70

5

88 Screening for colorectal cancer in ulcerative colitis. **1991**, 32, 721-3

87 From here to eternity - the secret of Pharaohs: Therapeutic potential of black cumin seeds and beyond. **2008**, 6, 495-510

102

86 Current management of inflammatory bowel disease and colorectal cancer. **2011**, 4, 53-61

87

85 Predictors of aggressive inflammatory bowel disease. **2011**, 7, 652-9

25

84	Colorectal cancer: a case control study of dietary factors, king faisal specialist hospital and research center, riyadh, saudi arabia. 2008 , 15, 57-64	12
83	Intestinal cancer in inflammatory bowel disease: natural history and surveillance guidelines. 2012 , 25, 193-200	6
82	Role of inflammation and inflammatory mediators in colorectal cancer. 2014 , 125, 358-72; discussion 372-3	34
81	Suitability of surveillance colonoscopy for patients with ulcerative colitis to detect colorectal cancer: current guidelines miss some early-stage cases. 2015 , 77, 237-44	5
80	Emerging Treatment Options in Mild to Moderate Ulcerative Colitis. 2015 , 11, 1-16	3
79	STAT3 is a key pathway in primary intraosseous squamous cell carcinoma arising from an odontogenic keratocyst. 2015 , 7, 1860-9	5
78	Paraoxonase-1 and arylesterase activities in patients with colorectal cancer. 2015 , 8, 21599-604	9
77	Advances in the Diagnosis and Management of Colonic Dysplasia in Patients With Inflammatory Bowel Disease. 2017 , 13, 357-362	4
76	Colorectal Cancer and Precancerous Lesions Associated with Ulcerative Colitis in Thailand. 2017 , 18, 2123-2126	1
75	siRNA Delivery for Control of Cyclin D1 and E2F1 Expression in Crohn's Disease. 2017 , 17, 22-30	
74	siRNA Delivery for Control of Cyclin D1 and E2F1 Expression in Crohn's Disease. 2017 , 17, 25-33	1
73	Long-term model of colitis-associated colorectal cancer suggests tumor spread mechanism and nature of cancer stem cells. 2021 , 21, 7	1
72	Anticancer therapeutics: a brief account on wide refinements. 2020 , 10, 3599-3621	1
71	Endoscopic Management of Complex Lesions in Patients With Inflammatory Bowel Disease. 2021 , 17, 121-127	
70	Colorectal Dysplasia and Cancer Surveillance in Ulcerative Colitis. 2021 , 9,	1
69	Health Maintenance for Adult Patients with Inflammatory Bowel Disease. 2021 , 1-14	0
68	Incidence of colorectal cancer in North-Western India over 5 Years. 2021 , 12, 165	0
67	Long-term model of colitis-associated colorectal cancer suggests tumor spread mechanism and nature of cancer stem cells. 2020 , 21, 1-1	1

- 66 Investigation of Calprotectin Positive Leukocytes in Canine Soft Tissue Tumors.
- 65 Intestinal Inflammation and Alterations in the Gut Microbiota in Cystic Fibrosis: A Review of the Current Evidence, Pathophysiology and Future Directions.. **2022**, 11, 4
- 64 Colitis ulcerosa. **2022**, 1-15
- 63 Inflammation, Chronic Disease, and Cancer: Is Psychological Distress the Common Thread?. **2022**, 1-19
- 62 Chronisch-entzündliche Darmerkrankungen: Morbus Crohn und Colitis ulcerosa. **2022**, 237-256
- 61 The pathophysiological role of macrophages in colitis and their treatment. **2022**, 277-297 o
- 60 Complications after bowel resection for inflammatory bowel disease associated cancer. A systematic literature review.. **2022**,
- 59 Characteristics and Outcomes of Left-sided Ulcerative Colitis With a Cecal/Periappendiceal Patch of Inflammation.. **2022**, o
- 58 Comorbidities in hereditary angioedema-A population-based cohort study.. **2022**, 12, e12135 2
- 57 Risk of Cancer in Inflammatory Bowel Disease and Pitfalls in Oncologic Therapy.. **2022**, 1 o
- 56 Risk Factors for Colorectal Polyps and Cancer.. **2022**, 32, 195-213 6
- 55 Colorectal Cancer: The Contribution of CXCL12 and Its Receptors CXCR4 and CXCR7.. **2022**, 14, 2
- 54 The Complex Network between Inflammation and Colorectal Cancer: A Systematic Review of the Literature.. **2021**, 13, 3
- 53 Persistent DNA damage and oncogenic stress-induced Trem1 promotes leukemia in mice.. **2022**,
- 52 Diagnosing gastrointestinal diseases from endoscopy images through a multi-fused CNN with auxiliary layers, alpha dropouts, and a fusion residual block. **2022**, 76, 103683 1
- 51 Neoplastic diseases of the small and large intestines. 1983-2043
- 50 Image_1.TIF. **2020**,
- 49 Image_2.tif. **2020**,

48	Image_3.TIF. 2020 ,	
47	Presentation_1.pdf. 2020 ,	
46	Presentation_2.pdf. 2020 ,	
45	Table_1.PDF. 2020 ,	
44	Table_2.PDF. 2020 ,	
43	Table_3.PDF. 2020 ,	
42	Table_4.pdf. 2020 ,	
41	Table_5.pdf. 2020 ,	
40	Table_6.xlsx. 2020 ,	
39	Table_1.docx. 2019 ,	
38	Table_2.DOCX. 2019 ,	
37	Table_3.DOCX. 2019 ,	
36	Table_4.DOCX. 2019 ,	
35	Table_5.DOCX. 2019 ,	
34	Table_6.DOCX. 2019 ,	
33	Clinicopathologic Features of Undetected Dysplasia Found in Total Colectomy or Proctocolectomy Specimens of Patients with Inflammatory Bowel Disease.. 2022 ,	o
32	Organic Carbon Monoxide Prodrugs that Release CO Under Physiological Conditions. 2022 , 232-258	
31	Inflammatory Bowel Diseases. 2022 , 281-299	

30	Risk of cancer in inflammatory bowel diseases: umbrella review and re-analysis of meta-analyses. 2022 ,	0
29	Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer. 12,	1
28	The Current Status of Molecular Biomarkers for Inflammatory Bowel Disease. 2022 , 10, 1492	2
27	Gut Microbiome in Inflammatory Bowel Disease: Role in Pathogenesis, Dietary Modulation, and Colitis-Associated Colon Cancer. 2022 , 10, 1371	1
26	Rumex japonicus Houtt. Extract Suppresses Colitis-Associated Colorectal Cancer by Regulating Inflammation and Tight-Junction Integrity in Mice. 13,	
25	A Novel Localization of the G-Protein-Coupled CysLT1 Receptor in the Nucleus of Colorectal Adenocarcinoma Cells. 2005 , 65, 732-742	20
24	COLORECTAL CANCER. 1997 , 35, 403-429	3
23	Colorectal Cancer in Ulcerative Colitis: Mechanisms, Surveillance and Chemoprevention. 2022 , 29, 6091-6114	0
22	Colorectal cancer in elderly-onset inflammatory bowel disease: A 1969-2017 Scandinavian register-based cohort study.	0
21	Increased histologic inflammation is an independent risk factor for nonconventional dysplasia in ulcerative colitis.	0
20	Biomimetic O ₂ Self-generated hybrid membrane nanoplatform for blocking the polarization towards immunosuppressive M2 macrophage phenotype and enhancing sonodynamics therapy in orthotopic colorectal cancer. 2022 , 450, 138337	1
19	Colorectal Cancer in Childhood-onset Inflammatory Bowel Disease: A Scandinavian Register-based Cohort Study, 1969-2017. 2022 , 75, 480-484	1
18	ADAM10 and ADAM17 as Biomarkers Linked to Inflammation, Metabolic Disorders and Colorectal Cancer. 2022 , 44, 4517-4527	0
17	Risk factors for colorectal cancer in IBD patients. 2022 , 140-146	0
16	Clinical features and oncological outcomes of intestinal cancers associated with ulcerative colitis and Crohn's disease.	0
15	Inflammatory Bowel Disease-related Cancer and Genomic Abnormalities. 2022 , 75, 473-477	0
14	Carcinoma of the Colon and Rectum. 1-26	0
13	Increased modified DUBLIN scores are associated with serious ulcerative colitis and treatment failure. 2022 , 15, 175628482211426	0

- 12 The HIF-prolyl hydroxylases have distinct and nonredundant roles in colitis-associated cancer. **2022**, 7, ○
- 11 Worsening Rhinosinusitis as a Prognostic Factor for Patients with Nasopharyngeal Carcinoma: A Retrospective Study. **2022**, 10, 3235 ○
- 10 F4/80+Ly6Chigh macrophages lead to cell plasticity and cancer initiation in colitis. **2023**, ○
- 9 Estrogen receptor beta expression in colitis-associated carcinoma in comparison with sporadic colonic tumor: An immunohistochemical study. ○
- 8 What Rectal Cancer Patients May Be Able to Safely Avoid Radiation?. **2022**, 18, 61-67 ○
- 7 Causes of Cancer and Mechanisms of Carcinogenesis. **2023**, 229-279 ○
- 6 Non-conventional dysplasia is frequently associated with low-grade tubuloglandular and mucinous adenocarcinomas in inflammatory bowel disease. ○
- 5 The Pathology of Chronic Inflammatory Bowel Disease. **2023**, 293-306 ○
- 4 Managing Risk of Dysplasia and Colorectal Cancer in Inflammatory Bowel Disease. **2023**, ○
- 3 What Is the Risk? Epidemiology and Evidence for Surveillance Regimens. ○
- 2 Dysplasies conventionnelles et non conventionnelles compliquant les maladies inflammatoires chroniques de l'intestin. **2023**, ○
- 1 Risk factors for postoperative recurrence of ulcerative colitis-associated colorectal cancer'. ○